Seelos Therapeutics (SEELQ) 10-K 28 Mar 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Mar. 14, 2019	Jun. 30, 2018
Document And Entity Information [Abstract]
Entity Registrant Name	Seelos Therapeutics, Inc.
Trading Symbol	SEEL
Entity Central Index Key	0001017491
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Is Entity's Reporting Status Current?	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Shell Company	false
Entity Public Float			$ 9.1
Entity Common Stock, Shares Outstanding		18,406,019

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Current assets
Cash	$ 3,579	$ 6,331
Prepaid expenses and other current assets	106	261
Total current assets	3,685	6,592
Property and equipment, net	38	79
Other long term assets	37	35
Total assets	3,760	6,706
Current liabilities
Accounts payable	235	58
Accrued expenses	644	650
Accrued compensation	272	863
Deferred revenue	0	12
Current liabilities of discontinued operations	21	0
Total current liabilities	1,172	1,583
Warrant liabilities	0	694
Other long term liabilities	16	58
Total liabilities	1,188	2,335
Commitments and contingencies (note 11)
Stockholders’ equity
Preferred stock, $.001 par value, 10,000,000 shares authorized, no shares issued or outstanding as of December 31, 2018 and 2017	0	0
Common stock, $.001 par value, 60,000,000 and 30,000,000 shares authorized, 941,553 and 507,241 issued and outstanding as of December 31, 2018 and 2017, respectively	28	15
Additional paid-in-capital	327,773	320,343
Accumulated deficit	(325,229)	(315,987)
Total stockholders’ equity	2,572	4,371
Total liabilities and stockholders’ equity	$ 3,760	$ 6,706

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Stockholders’ equity
Preferred stock, par value (in usd per share)	$ 0.001	$ 0.001
Preferred stock, authorized (in shares)	10,000,000	10,000,000
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0
Common stock, par value (in usd per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	60,000,000	30,000,000
Common stock, issued (in shares)	941,553	507,241
Common stock, outstanding (in shares)	941,553	507,241

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Operating expense
Research and development	$ 1,220	$ 3,463
General and administrative	7,928	7,210
Loss on disposal of assets	0	2
Total operating expense	9,148	10,675
Loss before other expense	(9,148)	(10,675)
Other income (expense)
Interest expense, net	0	(83)
Change in fair value of warrant liabilities	222	(646)
Loss on extinguishment of debt	0	(422)
Amendment of equity classified warrants	(293)	0
Other income, net	1	77
Total other expense	(70)	(1,074)
Loss from continuing operations	(9,218)	(11,749)
(Loss) income from discontinued operations	(24)	12,070
Net (loss) income	$ (9,242)	$ 321
Basic and diluted earnings (loss) per share
Continuing operations (in usd per share)	$ (12.11)	$ (29.64)
Discontinued operations (in usd per share)	(0.03)	30.45
Total earnings (loss) per share (in usd per share)	$ (12.14)	$ 0.81
Weighted average common shares outstanding for basic and diluted earnings (loss) per share (in shares)	761	396

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities:
Net (loss) income	$ (9,242)	$ 321
Net income (loss) from discontinued operations	(24)	12,070
Net loss from continuing operations	(9,218)	(11,749)
Adjustments to reconcile net loss to net cash used in operating activities from continuing operations:
Depreciation and amortization	41	117
Non-cash interest expense	0	56
Stock-based compensation expense	1,301	1,138
Warrant liabilities revaluation	(222)	646
Amendment of equity classified warrants	293	0
Loss on debt extinguishment	0	422
Other	0	2
Changes in operating assets and liabilities from continuing operations:
Prepaid expenses and other current assets	155	(84)
Other assets	(2)	25
Accounts payable	177	(705)
Accrued expenses	(6)	(681)
Accrued compensation	(591)	249
Deferred revenue	(12)	0
Other liabilities	(42)	(7)
Net cash used in operating activities from continuing operations	(8,126)	(10,571)
Cash flows from financing activities from continuing operations:
Issuance of common stock and warrants	4,792	10,733
Issuance costs related to common stock and warrants	(690)	(1,392)
Proceeds from exercise of warrants	1,275	289
Repayment of notes payable	0	(7,129)
Net cash provided by financing activities from continuing operations	5,377	2,501
Cash flows from discontinued operations:
Net cash (used in) provided by operating activities of discontinued operations	(3)	105
Net cash provided by investing activities of discontinued operations	0	12,209
Net cash provided by (used in) discontinued operations	(3)	12,314
Net (decrease) increase in cash	(2,752)	4,244
Cash, beginning of period	6,331	2,087
Cash, end of period	3,579	6,331
Supplemental disclosure of cash flow information:
Cash paid for interest	0	92
Cash paid for income taxes		0
Non-cash investing and financing activities:
Reclassification of warrant liabilities to equity	472	798
Issuance of placement agent warrants	$ 159	$ 287

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Beginning balance (in shares) at Dec. 31, 2016	258,000
Beginning balance at Dec. 31, 2016	$ 8	$ 308,784	$ (316,308)	$ (7,516)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	$ 0	1,138	0	1,138
Issuance of common stock and warrants (in shares)	245,000
Issuance of common stock and warrants	$ 7	10,726	0	10,733
Issuance of common stock due to the vesting of restricted stock, net of shares withheld to cover taxes (in shares)	4,000
Proceeds from exercise of warrants	$ 0	289	0	289
Issuance costs related to common stock and warrants	0	(1,392)	0	(1,392)
Reclassification of warrant liabilities to equity	0	798	0	798
Net income (loss)	$ 0	0	321	321
Ending balance (in shares) at Dec. 31, 2017	507,000
Ending balance at Dec. 31, 2017	$ 15	320,343	(315,987)	4,371
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	$ 0	1,301	0	1,301
Issuance of common stock and warrants (in shares)	390,000
Issuance of common stock and warrants	$ 12	4,780	0	4,792
Issuance of common stock due to the vesting of restricted stock, net of shares withheld to cover taxes (in shares)	10,000
Proceeds from exercise of warrants (in shares)	35,000
Proceeds from exercise of warrants	$ 1	1,274	0	1,275
Issuance costs related to common stock and warrants	0	(690)	0	(690)
Amendment of equity classified warrants	0	293	0	293
Reclassification of warrant liabilities to equity	$ 0	472	0	472
Net income (loss)			(9,242)	(9,242)
Ending balance (in shares) at Dec. 31, 2018	942,000
Ending balance at Dec. 31, 2018	$ 28	$ 327,773	$ (325,229)	$ 2,572

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Organization and Summary of Significant Accounting Policies	1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization Seelos Therapeutics, Inc. and Subsidiaries ("Seelos" or the "Company") is a Nevada corporation that was initially formed in 1987. The Company is a clinical-stage biopharmaceutical company focused on developing novel technologies and therapeutics for the treatment of central nervous system, respiratory and other disorders. Merger On January 24, 2019, the Company completed a reverse merger transaction (the "Merger") with Seelos Therapeutics, Inc., a Delaware corporation (now known as Seelos Corporation) ("STI"). Upon completion of the Merger, the Company changed its name to Seelos Therapeutics, Inc. and will focus on the development and commercialization of CNS therapeutics with known mechanisms of action in areas with a highly unmet medical need. On January 23, 2019, in connection with, and prior to the completion of, the Merger, the Company effected a reverse stock split of our common stock at a ratio of 1-for-30 (the "Reverse Stock Split"). Unless otherwise noted, references to share amounts, and other information have been adjusted to reflect the Reverse Stock Split. Shares of the Company's common stock commenced trading on the Nasdaq Capital Market under the ticker symbol "SEEL" as of market open on January 24, 2019. The Company's previous ticker symbol was "APRI". See note 2 below for more information regarding the Merger. These financial statements are of Apricus Biosciences, Inc. prior to the Merger because the Merger was consummated after the period covered by these financial statements. Accordingly, the historical financial information included in this Annual Report on Form 10-K, unless otherwise indicated or as the context otherwise requires, is that of Apricus Biosciences, Inc. prior to the Merger. The Company plans on developing its clinical and regulatory strategy with its internal research and development team with a view toward prioritizing market introduction as quickly as possible. The Company's lead programs following the completion of the merger are SLS-002 for the potential treatment of suicidality in post-traumatic stress disorder, and in major depressive disorder, SLS-005 for Sanfilippo syndrome and SLS-006 for the potential treatment of Parkinson's disease. Additionally, the Company is developing several preclinical programs, most of which have well-defined mechanisms of action, including: SLS-008 targeted at chronic inflammation in asthma and orphan indications such as pediatric esophagitis, SLS-010, in narcolepsy and related disorders and SLS-012, an injectable therapy for post-operative pain management. Basis of Presentation and Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of these consolidated financial statements in conformity with generally accepted accounting principles ("GAAP") requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. The Company's most significant estimates relate to the valuation of stock-based compensation, the valuation of its warrant liabilities, the impairment of long-lived assets and valuation allowances for the Company's deferred tax assets. The Company's actual results may differ from these estimates under different assumptions or conditions. Liquidity The accompanying consolidated financial statements have been prepared on a basis which assumes the Company is a going concern and that contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company had an accumulated deficit of approximately $325.2 million as of December 31, 2018. As of December 31, 2018, the Company had a cash balance of approximately $3.6 million. The Company also reported negative cash flows from operations of $8.1 million for the year ended December 31, 2018. The Company's history and other factors raise substantial doubt about the Company's ability to continue as a going concern. The Company has principally been financed through the sale of its common stock and other equity securities, debt financings, up-front payments received from commercial partners for the Company's products under development, and through the sale of assets. On September 20, 2018, the Company entered into a Securities Purchase Agreement (the "September 2018 SPA") with an accredited investor (the "Purchaser") for net proceeds of approximately $1.1 million. Pursuant to the September 2018 SPA, the Company sold 153,333 shares of the Company's common stock, at a purchase price of $8.10 per share and warrants to purchase up to 115,000 shares of common stock, exercisable six months after issuance at an exercise price equal to $9.00 per share, in a private placement. In addition, the Company issued warrants to purchase up to 7,667 shares of common stock to H.C. Wainwright (the "September 2018 Placement Agent Warrants"). The September 2018 Placement Agent Warrants are exercisable six months after issuance at an exercise price of $10.125 per share, and expire five years from the initial exercise date. The Company also issued additional warrants to the Purchaser in an amount of 89,239 shares of common stock, exercisable six months after issuance at an exercise price equal to $12.00 per share (all warrants issued to the Purchaser in the September 2018 SPA, the "September 2018 Warrants"). The September 2018 Warrants are exercisable for five years from the initial exercise date. In addition, pursuant to the terms of the September 2018 SPA, outstanding warrants to purchase up to 89,239 shares of common stock previously issued to and held by the Purchaser were canceled at the closing, which occurred on September 24, 2018. It is explicitly stated in the Form of Warrant for both the September 2018 Warrants and the September 2018 Placement Agent Warrants that under no circumstances would the Company be required to net cash settle the warrants. In connection with the September 2018 SPA, the Purchaser agreed to enter into a voting agreement with the Company to vote all of their respective shares of the Company's capital stock in favor of the adoption of the Merger Agreement. On June 22, 2018, the Company entered into a subscription agreement amendment (the "Subscription Agreement Amendment") with Sarissa Capital Domestic Fund LP ("Sarissa Domestic") and Sarissa Capital Offshore Master Fund LP ("Sarissa Offshore" and together with Sarissa Domestic, the "Investors"), which, among other things, removed the Investors' preemptive rights with respect to future issuances of the Company's equity securities. Concurrently with the Subscription Agreement Amendment, the Company entered into a warrant amendment (the "June 2018 Warrant Amendment") with Sarissa Offshore regarding the warrants to purchase common stock of the Company, issued in February 2015 (the "February 2015 Warrants") and January 2016 (together with the February 2015 Warrants, the "2015 and 2016 Warrants"), pursuant to which the exercise price of the warrants was reduced from $21.30 to $12.60 per share. Previously, in March 2018, the Company entered into a warrant amendment (the "March 2018 Warrant Amendment") with the holders of the 2015 and 2016 Warrants, which, among other things, (i) reduced the exercise price of the 2015 and 2016 Warrants from $264.00 to $21.3 per share, and (ii) amended certain provisions of the 2015 and 2016 Warrants such that they, effective as of the March 2018 Warrant Amendment, can no longer be net-cash settled. On April 2, 2018, the Company completed a public offering (the "April 2018 Financing") for net proceeds of approximately $3.1 million, after deducting placement agent fees and other estimated offering expenses. Pursuant to the agreement, the Company sold 236,667 units (the "2018 Units") at a purchase price of $15.00 per share, with each unit consisting of one share of the Company's common stock and one warrant to purchase 0.5 of a share of the Company's common stock (the "April 2018 Warrants"). The April 2018 Warrants have an exercise price equal to $15.00 per share of common stock and were exercisable following the Company's May 17, 2018 announcement that it had received stockholder approval of an amendment to its Amended and Restated Articles of Incorporation to increase the number of authorized shares of common stock to a total of 60,000,000 shares (the "2018 Charter Amendment") and the 2018 Charter Amendment became effective. The April 2018 Warrants will expire five years from that date. In addition, the Company issued warrants to purchase up to 11,833 shares of common stock (the "April 2018 Placement Agent Warrants") to H.C. Wainwright & Co., LLC ("H.C. Wainwright"). The April 2018 Placement Agent Warrants were exercisable upon the announcement of the effectiveness of the 2018 Charter Amendment at an exercise price of $18.75 per share, and also expire five years from that date. On September 10, 2017, the Company entered into a Securities Purchase Agreement (the "September 2017 SPA") with certain investors for net proceeds of approximately $3.1 million, after deducting commissions and estimated offering expenses payable by the Company. Pursuant to the agreement, the Company sold 71,220 shares of the Company's common stock at a purchase price of $51.90 per share, and warrants to purchase up to 35,610 shares of common stock in a private placement (the "September 2017 Warrants"). The September 2017 Warrants were originally exercisable upon closing, or on September 13, 2017, at an exercise price equal to $50.10 per share of common stock and are exercisable for two and one half years from that date. In addition, the Company issued warrants to purchase up to 3,561 shares of common stock to H.C. Wainwright (the "September 2017 Placement Agent Warrants"). The September 2017 Placement Agent Warrants were originally exercisable upon closing at an exercise price of $64.80 per share, and also expire two and one half years from the closing date. In connection with the April 2018 Financing, the September 2017 Warrants and the September 2017 Placement Agent Warrants were amended to, among other things, (i) reduce the exercise price of the warrants to $18.00 per share (the closing price of the Company's stock on March 27, 2018, or the date of the amendment), and (ii) change the date upon which such warrants became exercisable to the effective date of the 2018 Charter Amendment, or May 17, 2018 (the "April 2018 Warrant Amendment"). On April 26, 2017, the Company completed an underwritten public offering (the "April 2017 Financing") for net proceeds of approximately $5.9 million, after deducting the underwriting discounts and commissions and offering expenses payable by the Company. Pursuant to the underwriting agreement with H.C. Wainwright, the Company sold to H.C. Wainwright an aggregate of 167,667 units (the "2017 Units"). Each unit consisted of one share of common stock and one warrant to purchase 0.75 of a share of common stock (the "April 2017 Warrants"), sold at a public offering price of $42.00 per unit. At the time of the offering closing, the Company did not have a sufficient number of authorized common stock to cover shares of common stock issuable upon the exercise of the April 2017 Warrants. The sufficient number of authorized common stock became available on May 17, 2017 when the Company received stockholder approval of the proposed amendment to the Company's Amended and Restated Articles of Incorporation to increase the number of authorized shares of common stock (the "2017 Charter Amendment") and the 2017 Charter Amendment became effective on that date. The April 2017 Warrants will expire five years from May 17, 2017, the date they became exercisable, and the exercise price of the April 2017 Warrants is $46.50 per share of common stock. In connection with this transaction, the Company issued to H.C. Wainwright warrants to purchase up to 8,383 shares of common stock (the "2017 Underwriter Warrants"). The 2017 Underwriter Warrants have substantially the same terms as the April 2017 Warrants sold concurrently to the investors in the offering, except that the 2017 Underwriter Warrants have a term of five years from the effective date of the related prospectus, or April 20, 2017, and an exercise price of $52.50 per share. The common shares, warrants and warrant shares were issued and sold pursuant to an effective registration statement on Form S-1, which was previously filed with the SEC and declared effective on April 20, 2017, and a related prospectus. On April 20, 2017, the Company entered into a warrant amendment (the "April 2017 Warrant Amendment") with the holders of the Company's September 2016 Warrants (as defined below) issued in a financing in September 2016, (the "September 2016 Financing"), which, among other things, (i) reduced the exercise price of the September 2016 Warrants to $46.50 per share (the exercise price of the April 2017 Warrants), and (ii) changed the date upon which the September 2016 Warrants became exercisable to the effective date of the 2017 Charter Amendment, or May 17, 2017. On March 8, 2017, the Company entered into an asset purchase agreement (the "Ferring Asset Purchase Agreement") with Ferring International Center S.A. ("Ferring'), pursuant to which it sold to Ferring its assets and rights related to Vitaros outside of the United States for approximately $12.7 million, which consisted of an upfront payment of $11.5 million, approximately $0.7 million for the delivery of certain product-related inventory, and an aggregate of $0.5 million related to transition services. The Company used approximately $6.6 million of the proceeds from the sale to repay all outstanding amounts due and owed, including applicable termination fees, under its Loan and Security Agreement (the "Credit Facility") with Oxford Finance LLC ("Oxford") and Silicon Valley Bank ("SVB" and together as the "Lenders"). The Company currently has an effective shelf registration statement on Form S-3 filed with the Securities and Exchange Commission ("SEC") under which it may offer from time to time any combination of debt securities, common and preferred stock and warrants. As of December 31, 2018, the Company had approximately $95.2 million available under its Form S-3 shelf registration statement. Under current SEC regulations, at any time during which the aggregate market value of the Company's common stock held by non-affiliates ("public float"), is less than $75.0 million, the amount it can raise through primary public offerings of securities in any twelve-month period using shelf registration statements is limited to an aggregate of one-third of the Company's public float. SEC regulations permit the Company to use the highest closing sales price of the Company's common stock (or the average of the last bid and last ask prices of the Company's common stock) on any day within 60 days of sales under the shelf registration statement. While the Company's public float was greater than $75.0 million as of March 14, 2019, there is no guarantee that this will continue to be the case, and if the Company's public float were to fall below $75.0 million, the Company would be limited to an aggregate of one-third of its public float in the amount it could raise through primary public offerings of securities in any twelve-month period using shelf registration statements. The Company still would maintain the ability to raise funds through other means, such as through the filing of a registration statement on Form S-1 or in private placements. The rules and regulations of the SEC or any other regulatory agencies may restrict the Company's ability to conduct certain types of financing activities, or may affect the timing of and amounts it can raise by undertaking such activities. The accompanying consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern. The Company's future liquidity and capital funding requirements will depend on numerous factors, including: its ability to raise additional funds to finance its operations; its ability to maintain compliance with the listing requirements of The Nasdaq Capital Market ("Nasdaq"); the outcome, costs and timing of clinical trial results for the Company's current or future product candidates; litigation expenses and the extent and amount of any indemnification claims; the emergence and effect of competing or complementary products; its ability to maintain, expand and defend the scope of its intellectual property portfolio, including the amount and timing of any payments the Company may be required to make, or that it may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights; its ability to retain its current employees and the need and ability to hire additional management and scientific and medical personnel; the terms and timing of any collaborative, licensing or other arrangements that it has or may establish; the trading price of its common stock; and its ability to increase the number of authorized shares outstanding to facilitate future financing events. The Company will likely need to raise substantial additional funds through one or more of the following: issuance of additional debt or equity, or the completion of a licensing transaction for one or more of the Company's pipeline assets. If the Company is unable to maintain sufficient financial resources, its business, financial condition and results of operations will be materially and adversely affected. This could affect future development and business activities and potential future clinical studies and/or other future ventures. Failure to obtain additional equity or debt financing will have a material, adverse impact on the Company's business operations. There can be no assurance that the Company will be able to obtain the needed financing on acceptable terms or at all. Additionally, equity or debt financings will likely have a dilutive effect on the holdings of the Company's existing stockholders. On April 10, 2018, the Company was notified that, based on the previous thirty consecutive business days, the Company's common stock no longer met the minimum $1.00 bid price per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Requirement") and at that time, the Company was provided 180 calendar days, or until October 8, 2018, to regain compliance. On October 9, 2018, the Company received a letter from Nasdaq indicating that the Company's common stock has not regained compliance with the Bid Price Requirement. However, in accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an additional 180 calendar day period, or until April 8, 2019, to regain compliance. The Nasdaq Staff's determination that the Company is eligible for additional time is based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market, with the exception of the Bid Price Requirement, and the Company's written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If at any time before April 8, 2019, the closing bid price of the Company's common stock is at least $1.00 per share for a minimum of ten consecutive business days, the Nasdaq Staff will provide written confirmation of compliance with Rule 5550(a) and this matter will be closed. The Nasdaq letter has no immediate effect on the listing or trading of the Company's common stock and the common stock will continue to trade on The Nasdaq Capital Market under the symbol "APRI." The Company intends to monitor the bid price of its common stock and consider available options if its common stock does not trade at a level likely to result in the Company regaining compliance with the Bid Price Requirement by April 8, 2019. If compliance cannot be demonstrated by April 8, 2019, the Nasdaq Staff will provide written notification that the Company's common stock will be delisted. At that time, the Company may appeal the Nasdaq Staff's determination to a Hearings Panel. On February 7, 2019, the Company was notified by the Nasdaq Staff that for more than the last 10 consecutive business days, from January 24, 2019 through February 6, 2019, the closing bid price of the Company's common stock had been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2), and this matter is now closed. Warrant Liabilities Prior to 2018, the Company's 2015 and 2016 Warrants were classified as liabilities in the accompanying consolidated 2017 balance sheet as they contained provisions that were considered outside of the Company's control, such as requiring the Company to maintain active registration of the shares underlying such warrants. The 2015 and 2016 Warrants were recorded at fair value using the Black-Scholes option pricing model. The fair value of these warrants was re-measured at each financial reporting period with any changes in fair value being recognized as a component of other income (expense) in the accompanying consolidated statements of operations for 2017. In March 2018, the Company entered into the March 2018 Warrant Amendment with the holders of its 2015 and 2016 Warrants, which amended the terms so that in no circumstances may the 2015 and 2016 Warrants be net-cash settled. As a result, the fair value of the 2015 and 2016 Warrants at the date of the modification were reclassified to equity. All of the Company's outstanding warrants, other than the Pre-Merger Warrants, have similar terms whereas under no circumstance may the warrants be net-cash settled. As such, all warrants are equity-classified. See note 7 for further details. Fair Value of Financial Instruments The Company's financial instruments consist principally of accounts payable, accrued expenses, and historically, its Credit Facility with the Lenders. The carrying amounts of financial instruments such as accounts receivable, accounts payable and accrued expenses approximate their related fair values due to the short-term nature of these instruments. Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Depreciation is provided on a straight-line basis over the estimated useful lives of the assets. The Company estimates useful lives as follows: Machinery and equipment: three to five years Furniture and fixtures: ten years Computer software: five years Amortization of leasehold improvements and capital lease equipment is provided on a straight-line basis over the shorter of their estimated useful lives or the lease term. The costs of additions and betterments are capitalized, and repairs and maintenance costs are charged to operations in the periods incurred (see note 5 for further details). Leases Leases are reviewed and classified as capital or operating at their inception. Historically, the Company recorded rent expense associated with its operating lease on a straight-line basis over the term of the lease. The difference between rent payments and straight-line rent expense was recorded as deferred rent in accrued liabilities. In January 2018, the Company subleased a portion of its office space. During the first quarter of 2018, the Company recorded a liability for the present value of the remaining lease due, offset by the sublease income reasonably expected over the remaining term of the lease. Fair Value Measurements The Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established by accounting guidance and prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The Company's common stock warrant liabilities were measured and disclosed at fair value on a recurring basis, and were classified within the Level 3 designation. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability. In March 2018, the Company entered into the March 2018 Warrant Amendment with the holders of its 2015 and 2016 Warrants, which amended the terms so that in no circumstances may the 2015 and 2016 Warrants be net-cash settled. As a result, the Company's 2015 and 2016 Warrants were reclassified from liabilities to equity during the first quarter of 2018 and will no longer be measured at fair value on a recurring basis. The following table presents the Company's fair value hierarchy for its warrant liabilities measured at fair value on a recurring basis (in thousands) as of December 31, 2017: Quoted Market Significant Prices for Other Significant Identical Observable Unobservable Assets Inputs Inputs Warrant liabilities (Level 1) (Level 2) (Level 3) Total Balance as of December 31, 2017 $ - $ - $ 694 $ 694 The common stock warrant liabilities were recorded at fair value using the Black-Scholes option pricing model. There were no liabilities classified as warrants as of December 31, 2018. The following assumptions were used in determining the fair value of the common stock warrant liabilities valued using the Black-Scholes option pricing model as of December 31, 2017: December 31, 2017 Risk-free interest rate 2.2%-2.2% Volatility 89%-89.41% Dividend yield - % Expected term 5.04-5.17 Weighted average fair value $ 24.00 The following table is a reconciliation for the common stock warrant liabilities measured at fair value using Level 3 unobservable inputs (in thousands): Warrant liabilities Balance as of December 31, 2017 $ 694 Change in fair value measurement of warrant liability (222) Warrant liability reclassified to stockholders' equity (472) Balance as of December 31, 2018 $ - Of the inputs used to value the outstanding common stock warrant liabilities as of December 31, 2018, the most subjective input is the Company's estimate of expected volatility of its common stock. Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss is recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than it's carrying amount. If such assets are considered impaired, the amount of the impairment loss recognized is measured as the amount by which the carrying value of the asset exceeds the fair value of the asset, fair value being determined based upon future cash flows or appraised values, depending on the nature of the asset. The Company recognized no impairment losses during either of the periods presented within its financial statements. Research and Development Research and development costs are expensed as incurred and include the cost of compensation and related expenses, as well as expenses for third parties who conduct research and development on the Company's behalf, pursuant to development and consulting agreements in place. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. The Company also follows the provisions of accounting for uncertainty in income taxes which prescribes a model for the recognition and measurement of a tax position taken or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure and transition. Income (Loss) Per Common Share Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the same period. Diluted net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares and common equivalent shares outstanding during the same period. Common equivalent shares may be related to stock options, restricted stock units, or warrants. The Company excludes common stock equivalents from the calculation of diluted net income (loss) per share when the effect is anti-dilutive. The following securities that could potentially decrease net income (loss) per share in the future are not included in the determination of diluted income (loss) per share as their effect is anti-dilutive (in thousands): Year Ended December 31, 2018 2017 Outstanding stock options 29 12 Outstanding warrants 437 236 Restricted stock units 9 24 475 272 Stock-Based Compensation The estimated grant date fair value of stock options granted to employees and directors is calculated based upon the closing stock price of the Company's common stock on the date of the grant and recognized as stock-based compensation expense over the expected service period, which is typically approximated by the vesting period. The Company estimates the fair value of each option award on the date of grant using the Black-Scholes option pricing model. The value of restricted stock unit grants is calculated based upon the closing stock price of the Company's common stock on the date of the grant. Segment Information The Company operates under one segment which develops pharmaceutical products. Geographic Information Revenues (included in discontinued operations) by geographic area for the Company's operations are as follows (in thousands): Year Ended December 31, 2018 2017 Europe (1)(2) $ - $ 364 Canada (1) - 142 Other (1)(2) - 5 $ - $ 511 (1) As a result of the Ferring Asset Purchase Agreement, all revenues have been reflected as discontinued operations in the statement of operations for all periods presented. (2) Amounts included have not been broken out by country as it is impractical to do so given the nature and structure of the license agreements which cover multiple countries and/or territories. The basis for attributing product sales and royalty revenues from external customers to individual countries was based on the geographic location of the end user customer. All of the Company's net long-lived assets were located in the United States for each of the years ended December 31, 2018 and 2017, respectively. Recent Accounting Pronouncements In May 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. ASU 2016-12, Revenue from Contracts with Customers In February 2016, the FASB issued ASU 2016-2, Leases

Merger

Merger	12 Months Ended
	Dec. 31, 2018
Business Combinations [Abstract]
Merger	2. MERGER On January 24, 2019, the Company completed its business combination with STI in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of July 30, 2018 (the "Merger Agreement"), by and among the Company, Arch Merger Sub, Inc. ("Merger Sub"), and STI, as amended by Amendment No. 1 thereto made and entered into as of October 16, 2018 (the "First Amendment"), Amendment No. 2 thereto made and entered into as of December 14, 2018 (the "Second Amendment") and Amendment No. 3 thereto made and entered into as of January 16, 2019 (the "Third Amendment" and the Merger Agreement, as amended by the First Amendment, Second Amendment and Third Amendment, the "Amended Merger Agreement"), pursuant to which Merger Sub merged with and into STI, with STI surviving as the Company's wholly-owned subsidiary. On January 23, 2019, in connection with, and prior to the completion of, the Merger, the Company effected a reverse stock split of its common stock, par value $0.001 per share, at a ratio of 1-for-30 (the "Reverse Stock Split"), and on January 24, 2019, immediately after completion of the Merger, the Company changed its name to "Seelos Therapeutics, Inc." Following the completion of the Merger, the business conducted by the Company became primarily the business conducted by STI, which is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system disorders. Under the terms of the Amended Merger Agreement, the Company issued shares of its common stock to the stockholders of STI at an exchange rate of 0.7704 shares of its common stock, after taking into account the Reverse Stock Split, for each share of STI's common stock outstanding immediately prior to the Merger. The exchange rate was determined through arms'-length negotiations between the Company and the STI. The Company also assumed all of the stock options outstanding under STI's 2016 Equity Incentive Plan (the "2016 Plan") with such stock options henceforth representing the right to purchase a number of shares of the Company's common stock equal to 0.7704 multiplied by the number of shares of STI's common stock previously represented by such options. Immediately after the Merger, there were approximately 6,221,822 shares of the Company's common stock outstanding, subject to rounding up any fractional shares as a result of the Reverse Stock Split as further described below. Immediately after the Merger, the former stockholders, optionholders and noteholders of STI owned, or held rights to acquire, approximately 84.85% of the fully-diluted shares of the Company's common stock, which for these purposes is defined as the outstanding shares of common stock, plus restricted stock units and "in the money" options and warrants to purchase shares of Common Stock, assuming that all of its "in the money" options and warrants outstanding immediately prior to the Merger were exercised on a cashless basis immediately prior to the closing of the Merger (the "Fully-Diluted Capitalization"), with its stockholders, optionholders, restricted stock unit holders and warrantholders immediately prior to the Merger owning, or holding rights to acquire, approximately 15.15% of the Fully-Diluted Capitalization. The shares of common stock issued to the former stockholders of STI were registered with the SEC. The shares of the Company's common stock listed on the Nasdaq Capital Market, previously trading through the close of business on January 23, 2019 under the ticker symbol "APRI," commenced trading on the Nasdaq Capital Market, on a post-Reverse Stock Split adjusted basis, under the ticker symbol "SEEL" on January 24, 2019. Contingent Value Rights Agreement Upon the closing of the Merger, the Company, STI, Richard Pascoe, as representative of the Company's stockholders, and a rights agent entered into the Contingent Value Rights Agreement (the "CVR Agreement"). Pursuant to the CVR Agreement, Company stockholders will receive one CVR for each share of the Company's common stock held of record immediately prior to the closing of the Merger. Each CVR will represent the right to receive payments based on the Company's Vitaros assets. In particular, CVR holders will be entitled to receive 90% of any cash payments (or the fair market value of any non-cash payments) exceeding $500,000 received, during a period of ten years from the closing of the Merger, based on the sale or out-licensing of the Vitaros assets, including any contingent payments, less reasonable transaction expenses. The Company is entitled to retain the first $500,000 and 10% of any contingent payments. In order to be eligible for the CVR, a Company stockholder must have been a holder of record at the close of business immediately prior to the closing of the Merger. The Company agreed to use commercially reasonable efforts to out-license or sell the Vitaros assets for a period of three years following the closing of the Merger. The CVRs are not be transferable, except in limited circumstances and will not be registered with the SEC. Richard Pascoe, the Company's former President and CEO, was appointed to serve as the representative of the CVR holders' interests under the CVR Agreement.

Ferring Asset Purchase Agreemen

Ferring Asset Purchase Agreement and Discontinued Operations	12 Months Ended
	Dec. 31, 2018
Discontinued Operations and Disposal Groups [Abstract]
Ferring Asset Purchase Agreement and Discontinued Operations	3. FERRING ASSET PURCHASE AGREEMENT AND DISCONTINUED OPERATIONS On March 8, 2017, the Company entered into the Ferring Asset Purchase Agreement, pursuant to which, and on the terms and subject to the conditions thereof, among other things, the Company agreed to sell to Ferring its assets and rights (the "Purchased Assets") related to the business of developing, marketing, distributing, and commercializing, outside the United States, the Company's products currently marketed or in development, intended for the topical treatment of sexual dysfunction (the "Product Business"), including products sold under the name Vitaros (the "Products") for approximately $12.7 million. The Purchased Assets include, among other things, certain pending and registered patents and trademarks, contracts, manufacturing equipment and regulatory approvals relating to the Products outside of the United States. The Company retained the U.S. development and commercialization rights for Vitaros and a license from Ferring (the "Ferring License") for intellectual property rights for Vitaros and other products which relate to development both within the United States and internationally. Pursuant to the terms of the Ferring Asset Purchase Agreement, Ferring paid the Company $11.5 million in cash at closing and paid approximately $0.7 million for the value of inventory related to the Products in April 2017. The Company was also eligible to receive two additional quarterly payments totaling $0.5 million for transition services, the first of which was received in July 2017 and the second of which was received in September 2017. The Company used a portion of the proceeds from the sale of the Purchased Assets to repay all amounts owed, including applicable termination fees, under the Credit Facility, which was approximately $6.6 million. The extinguishment of the Credit Facility was a stipulation of the Ferring Asset Purchase Agreement; however, since it was corporate debt, the loss on extinguishment was not offset against the gain on the sale of the Purchased Assets. As of the transaction date, Ferring assumed responsibility for future obligations under the purchased contracts and regulatory approvals, as well as other liabilities associated with the Purchased Assets arising after the closing date, including $1.1 million, the remainder of the installment payments owed by the Company to Sandoz as a condition under the termination agreement between the two parties. The Company retained all liabilities associated with the Purchased Assets arising prior to the closing date. Under the Ferring Asset Purchase Agreement, the Company has also agreed to indemnify Ferring for, among other things, breaches of its representations, warranties and covenants, any liability for which it remains responsible and its failure to pay certain taxes or comply with certain laws, subject to a specified deductible in certain cases. The Company's aggregate liability under such indemnification claims is generally limited to $2.0 million. At the closing of the Ferring Asset Purchase Agreement, the Company entered into the Ferring License with respect to certain intellectual property rights necessary to or useful for its exploitation of the Purchased Assets within the United States and for its exploitation of the Purchased Assets in certain fields outside of sexual dysfunction, including for the treatment of Raynaud's Phenomenon, outside the United States. The parties granted one another a royalty free, perpetual and non-exclusive license to product know-how in their respective fields and territories and Ferring granted the Company a royalty-free, perpetual and exclusive license to certain patents in the field of sexual dysfunction in the United States and in certain fields other than sexual dysfunction outside of the United States. The Ferring Asset Purchase Agreement was treated as a sale of a business and the total proceeds from the sale were allocated to the Purchased Assets. The total gain on sale of the Purchased Assets to Ferring consisted of the following: Upfront payment received $ 11,500 Transition services payments 500 Payment received for inventory 709 Total proceeds from sale $ 12,709 Carrying value of assets sold in sale (1,578) Liabilities transferred upon sale 1,186 Total gain on sale of Purchased Assets $ 12,317 Discontinued Operations The Company had $0.02 million in accrued expenses related to discontinued operations as of December 31, 2018. There were no assets and liabilities presented as discontinued operations as of December 31, 2017. The operating results of the Company's discontinued operations are as follows (in thousands): Year Ended December 31, 2018 2017 Product sales $ - $ 143 Royalty revenue - 368 Cost of goods sold (24) (74) Cost of Sandoz rights - (10) Operating expenses - (658) Other expense - (16) Gain on sale - 12,317 (Loss) income from discontinued operations $ (24) $ 12,070 Product sales, royalty revenue and cost of goods sold all relate to the sale of Vitaros product outside of the United States. Historically, the Company relied on its former commercial partners to sell Vitaros in approved markets and received royalty revenue from its former commercial partners based upon the amount of those sales. Royalty revenues were computed and recognized on a quarterly basis, typically one quarter in arrears, and at the contractual royalty rate pursuant to the terms of each respective license agreement. The Company recorded $0.4 million in royalty revenue during the year ended December 31, 2017 related to sales of Vitaros prior to the completion of the Ferring Asset Purchase Agreement, during the fourth quarter of 2016 and the first quarter of 2017. "Cost of Sandoz rights" represents the payments owed by the Company to Sandoz as a condition under the termination agreement between the two parties related to Vitaros outside of the United States. Operating expenses for the current periods include primarily patent and legal fees and accounting expenses incurred in connection with the Ferring Asset Purchase Agreement.

Allergan and Forendo In-Licensi

Allergan and Forendo In-Licensing Agreement	12 Months Ended
	Dec. 31, 2018
In-Licensing Agreement [Abstract]
Allergan and Forendo In-Licensing Agreement	4. ALLERGAN IN-LICENSING AGREEMENT In 2009, Warner Chilcott Company, Inc., now a subsidiary of Allergan, acquired the commercial rights to Vitaros in the United States. In September 2015, the Company entered into a license agreement and amendment to the original agreement with Warner Chilcott Company, Inc., granting the Company exclusive rights to develop and commercialize Vitaros in the United States in exchange for a $1.0 million upfront payment, paid in September 2015, and a $1.5 million regulatory milestone payment, paid in September 2017 following the FDA's acknowledgment of receipt of the Company's NDA resubmission. Since the intangibles acquired in the license agreement do not have alternative future use, all costs incurred including the upfront payment and the regulatory milestone payment, were treated as research and development expense. As part of the license agreement, Allergan has the right to exercise a one-time opt-in right to assume all future commercialization activities in the United States, assuming FDA approval, in exchange for a total of $25.0 million in upfront and potential launch milestone payments owed to the Company for that right, plus a high double-digit royalty in the ten to twenty percent range on Allergan's net sales of the product. If Allergan elects not to exercise its opt-in right, the Company may commercialize Vitaros, and in return, pay Allergan a high double-digit royalty in the ten to twenty percent range on our net sales of the product. In 2008, the FDA issued a complete response letter (the "2008 CRL") for the Vitaros NDA, identifying certain deficiencies in the application. Based on the Company's subsequent interactions with the FDA and after completion of further drug-device engineering and other activities intended to address issues previously raised in the 2008 CRL, which included human factor testing and new non-clinical studies, the Company resubmitted the Vitaros NDA in August 2017. On February 15, 2018, the FDA issued a CRL indicating that the modest treatment effect did not outweigh certain safety concerns specific to the 2.5% concentration of its permeation enhancer NexACT (DDAIP.HCl) contained in the current formulation and identifying deficiencies related to chemistry, manufacturing and controls. In April 2018, the Company met with the FDA and confirmed that two new Phase 3 clinical efficacy trials would be necessary at a lower formulation concentration in order to potentially reach approval.

Other Financial Information

Other Financial Information	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Other Financial Information	5. OTHER FINANCIAL INFORMATION Property and Equipment Property and equipment are comprised of the following (in thousands): December 31, 2018 2017 Leasehold improvements $ 20 $ 20 Machinery and equipment 270 270 Capital lease equipment 76 76 Computer software 130 130 Furniture and fixtures 25 25 Total property and equipment 521 521 Less: accumulated depreciation and amortization (483) (442) Property and equipment, net $ 38 $ 79 Depreciation expense totaled $0.04 million and $0.1 million for the years ended December 31, 2018 and 2017, respectively. Accrued Expenses Accrued expenses are comprised of the following (in thousands): December 31, 2018 2017 Professional fees $ 548 $ 575 Outside research and development services 4 61 Other 92 14 Accrued expenses, net $ 644 $ 650 Other Long Term Liabilities Other long term liabilities are comprised of the following (in thousands): December 31, 2018 2017 Deferred rent $ 4 $ 46 Security deposit 12 12 Other long term liabilities, net $ 16 $ 58

Debt

Debt	12 Months Ended
	Dec. 31, 2018
Warrants Expiring March 2023, Tranche 2 [Member]
Debt	6. DEBT Credit Facility On October 17, 2014 (the "Closing Date"), the Company entered into the Credit Facility with the Lenders, pursuant to which the Lenders agreed, subject to certain conditions, to make term loans totaling up to $10.0 million available to the Company. The first $5.0 million term loan was funded on the Closing Date. A second term loan of $5.0 million was funded at the Company's request on July 23, 2015. The first and second term loans had annual interest rates of 7.95% and 8.01%, respectively. The repayment schedule provided for interest-only payments in arrears until November 2015, followed by consecutive equal monthly payments of principal and interest in arrears through the original maturity date, which was October 1, 2018 (the "Maturity Date"). On the Closing Date, the Company issued warrants to purchase up to an aggregate of 646 shares of common stock at an exercise price of $387.00 per share to the Lenders. On July 23, 2015, in connection with the funding of the second term loan, the Company issued additional warrants to purchase up to an aggregate of 508 shares of common stock at an exercise price of $492.00 per share to the Lenders. The warrants were exercisable upon issuance and expire ten years from their dates of issuance. The warrants were classified in equity since they do not include provisions that would require the Company to repurchase its shares or cash settle, among other factors that would require liability classification. The fair value of the warrants at issuance of approximately $0.1 million was initially recorded as a discount to the principal balance and was being amortized over the life of the Credit Facility using the effective interest method. As a result of the prepayment of the Credit Facility in March 2017, the remaining discount was also written off. On March 8, 2017, pursuant to the Ferring Asset Purchase Agreement, the Company repaid to the Lenders all amounts due and owed in full under the Credit Facility. Per the Credit Facility, the Company was subject to a prepayment fee of up to 3% since prepaying the outstanding balance of the term loans in full prior to the Maturity Date. Upon repayment of each term loan, the Company was also required to make a final payment to the Lenders equal to 6% of the original principal amount of each term loan. This final payment had been partially accreted over the life of the Credit Facility using the effective interest method. The final payment included the outstanding balance of the term loans in full as well as (i) a prepayment fee of approximately 2%, or $0.1 million, (ii) a final payment equal to 6% of the original principal amount of each term loan, or $0.6 million, and (iii) per diem interest of approximately $0.05 million, for a total payment of $6.6 million. The Company's notes payable balance was zero for each of the years ended December 31, 2018 and 2017, respectively. The Company recognized interest expense related to the Credit Facility of $0 and $0.1 million during the years ended December 31, 2018 and 2017, respectively. Although the extinguishment of the debt was a closing condition of the Ferring Asset Purchase Agreement, since the Credit Facility was related to corporate debt, the loss on extinguishment and related interest expense is presented on the consolidated statements of operations as continuing operations.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Stockholders' Equity	7. STOCKHOLDERS' EQUITY Preferred Stock The Company is authorized to issue 10.0 million shares of preferred stock, par value $0.001, of which 1.0 million shares are designated as Series A Junior Participating Preferred Stock, 800 are designated as Series B 8% Cumulative Convertible Preferred Stock, and 600 are designated as Series C 6% Cumulative Convertible Preferred Stock. No shares of preferred stock were outstanding as of December 31, 2018 or 2017. Common Stock Offerings September 2018 Financing On September 20, 2018, the Company entered into a Securities Purchase Agreement (the "September 2018 SPA") with an investor (the "Purchaser") for net proceeds of approximately $1.1 million. Pursuant to the September 2018 SPA, the Company sold 153,333 shares of the Company's common stock, at a purchase price of $8.10 per share and warrants to purchase up to 115,000 shares of common stock, exercisable six months after issuance at an exercise price equal to $9.00 per share, in a private placement. In addition, the Company issued warrants to purchase up to 7,667 shares of common stock to H.C. Wainwright (the "September 2018 Placement Agent Warrants"). The September 2018 Placement Agent Warrants are exercisable six months after issuance at an exercise price of $10.125 per share, and expire five years from the initial exercise date. The Company also issued additional warrants to the Purchaser in an amount of 89,239 shares of common stock, exercisable six months after issuance at an exercise price equal to $12.00 per share (all warrants issued to the Purchaser in the September 2018 SPA, the "September 2018 Warrants"). The September 2018 Warrants are exercisable for five years from the initial exercise date. It is explicitly stated in the Form of Warrant for both the September 2018 Warrants and the September 2018 Placement Agent Warrants that under no circumstances would the Company be required to net cash settle the warrants. In connection with the September 2018 SPA, the Purchaser agreed to enter into a voting agreement with the Company to vote all of their respective shares of the Company's capital stock in favor of the adoption of the Merger Agreement. The total initial $0.9 million fair value of the combined warrants was determined using the Black-Scholes option pricing model and was recorded to equity. The September 2018 Warrants and the September 2018 Placement Agent Warrants were classified as equity and valued using assumptions of an expected term of 5.5 years for each, a volatility of 107.3% for each, annual rate of dividends of 0% for each, and risk-free interest rates of 2.97% for each. Transaction costs of approximately $0.2 million were netted against the proceeds allocated to the common stock shares in equity. In addition, pursuant to the terms of the September 2018 SPA, outstanding warrants to purchase up to 89,239 shares of common stock previously issued to and held by the Purchaser were cancelled at the closing, which occurred on September 24, 2018. The fair value of the exchange between the warrants previously issued and outstanding prior to the September 2018 SPA and those issued in replacement of those warrants was $0.6 million on the date of the modification, which resulted in a charge of $0.1 million to amendment of equity classified warrants on the consolidated statements of operations. June 2018 Warrant Amendment On June 22, 2018, the Company entered into the Subscription Agreement Amendment with the Investors, which, among other things, removed the Investors' preemptive rights with respect to future issuances of the Company's equity securities. Concurrently with the Subscription Agreement Amendment, the Company entered into the June 2018 Warrant Amendment with Sarissa Offshore regarding the 2015 and 2016 Warrants, pursuant to which the exercise price of the warrants was reduced from $21.30 to $12.60 per share. The amendment to the warrants resulted in a charge of approximately $17,000, which was recorded as amendment of equity classified warrants expense during the three months ended June 30, 2018. March 2018 Warrant Amendment In March 2018, the Company entered into the March 2018 Warrant Amendment with the holders of the 2015 and 2016 Warrants, which, among other things, (i) reduced the exercise price of the 2015 and 2016 Warrants from $264.00 to $21.30 per share, and (ii) amended certain provisions of the 2015 and 2016 Warrants such that they can no longer be net- cash settled. The fair value of the 2015 and 2016 Warrants on the date of the modification was $0.5 million, which resulted in a charge of $0.2 million to amendment of equity classified warrants on the consolidated statements of operations. Upon modification, the 2015 and 2016 Warrants were reclassified to stockholders' equity. April 2018 Financing & Warrant Amendment On April 2, 2018, the Company completed the April 2018 Financing for net proceeds of approximately $3.1 million, after deducting placement agent fees and other estimated offering expenses for the sale. Pursuant to the agreement, the Company sold 236,667 of the Company's 2018 Units. The April 2018 Warrants issued pursuant to the April 2018 Financing have an exercise price equal to $15.00 per share of common stock, and are only exercisable following the Company's announcement that it has received stockholder approval of the 2018 Charter Amendment and the effective date of the 2018 Charter Amendment. The April 2018 Warrants will expire five years from the date they are first exercisable. In addition, the Company issued the April 2018 Placement Agent Warrants to purchase up to 11,833 shares of common stock to H.C. Wainwright. The April 2018 Placement Agent Warrants are exercisable upon the announcement of the effectiveness of the 2018 Charter Amendment at an exercise price of $18.75 per share, and also expire five years from that date. It is explicitly stated in the Form of Warrant for both the April 2018 Warrants and the Placement Agent Warrants that under no circumstances may the shares be settled in cash. The total initial $1.2 million fair value of the combined warrants was determined using the Black-Scholes option pricing model and was recorded to equity. The April 2018 Warrants and the April 2018 Placement Agent Warrants were classified as equity and valued using assumptions of expected terms of 5.12 years and 5.0 years, volatilities of 104.0% and 105%, respectively, annual rate of dividends of 0%, and risk-free interest rates of 2.55% for each. Transaction costs of approximately $0.7 million were netted against the proceeds allocated to the common stock shares in equity. In connection with the April 2018 Financing, the Company entered into a warrant amendment with the holders of the Company's warrants to purchase common stock of the Company, issued in the September 2017 Financing. See below for details. September 2017 Financing On September 10, 2017, the Company entered into the September 2017 SPA with certain accredited investors for net proceeds of approximately $3.1 million. Pursuant to the agreement, the Company sold 71,220 shares of the Company's common stock at a purchase price of $51.90 per share and the September 2017 Warrants. The September 2017 Warrants were exercisable upon closing, or on September 13, 2017, at an exercise price equal to $50.10 per share of common stock and are exercisable for two and one-half years from that date. In addition, the Company issued the September 2017 Placement Agent Warrants. The September 2017 Placement Agent Warrants were exercisable upon closing at an exercise price of $64.80 per share, and also expire two and one-half years from the closing date. The standalone fair value of the combined warrants was determined using the Black-Scholes option pricing model and was recorded to equity. The September 2017 Warrants and September 2017 Placement Agent Warrants were valued using assumptions of expected terms of 2.5 for each, volatilities of 110.4% for each, annual rate of dividends of 0.0% for each, and risk-free interest rates of 1.38% for each. The terms of the warrants state that under no circumstance may the shares be settled in cash. Therefore, the September 2017 Warrants and the September 2017 Placement Agent Warrants have been classified within stockholders' equity. The total proceeds from the private placement were allocated to the common stock and warrants on a relative fair values basis, with $2.8 million attributed to the common stock and $0.9 million attributed to the warrants. Transaction costs of approximately $0.6 million were netted against the proceeds and allocated to the common stock shares in equity. In connection with the April 2018 Financing, the Company entered in the April 2018 Warrant Amendment, which (i) reduced the exercise price of the September 2017 Warrants and the September 2017 Placement Agent Warrants to $18.00 per share (the closing price of the Company's stock on March 27, 2018, the date of the amendment), and (ii) changed the date upon which such warrants become exercisable to the effective date of the 2018 Charter Amendment. The April 2018 Warrant Amendment resulted in a charge of approximately $0.1 million, which was recorded as amendment of equity classified warrants in the consolidated statement of operations for the year ended December 31, 2018. April 2017 Financing & Warrant Amendment On April 26, 2017, the Company completed the April 2017 Financing for net proceeds of approximately $5.9 million, after deducting the underwriting discounts and commissions and offering expenses payable by the Company. Pursuant to the underwriting agreement with H.C. Wainwright, the Company sold to H.C. Wainwright an aggregate of 167,667 units. Each unit consisted of one share of common stock and one warrant to purchase 0.75 of a share of common stock, sold at a public offering price of $42.00 per unit. The April 2017 Warrants became exercisable only following the Company's announcement that it has received stockholder approval of the effectiveness of the 2017 Charter Amendment and the 2017 Charter Amendment had become effective. The April 2017 Warrants were exercisable upon the effective date of the 2017 Charter Amendment on May 17, 2017, expire five years from such date and have an exercise price $46.50 per share of common stock. In connection with this transaction, the Company issued to H.C. Wainwright the 2017 Underwriter Warrants. The 2017 Underwriter Warrants have substantially the same terms as the 2017 Warrants, except that the 2017 Underwriter Warrants have a term of five years from April 20, 2017 and an exercise price of $52.50 per share. The terms of the April 2017 Warrants and the April 2017 Underwriter Warrants state that under no circumstance may the shares be settled in cash. Therefore, the April 2017 Warrants and the April 2017 Underwriter Warrants have been classified within stockholders' equity. The common shares, warrants and warrant shares were issued and sold pursuant to an effective registration statement on Form S-1, which was previously filed with the SEC and declared effective on April 20, 2017, and a related prospectus. The total initial $2.9 million fair value of the combined warrants was determined using the Black-Scholes option pricing model and was recorded to equity. The warrants and Underwriter Warrants were valued using assumptions of expected terms of 5.06 and 5.0 years, respectively, volatilities of 88.3% and 88.7%, respectively, annual rate of dividends of 0.0% for each, and risk-free interest rates of 1.8% for each. Transaction costs of approximately $1.1 million were netted against the proceeds allocated to the common stock shares in equity. Pursuant to the April 2017 Financing, the Company entered into a warrant amendment with the holders of the Company's warrants to purchase common stock of the Company, issued in the September 2016 Financing. See below for details. September 2016 Financing In September 2016, the Company completed the September 2016 Financing, which was a registered direct offering of 36,080 shares of common stock at a purchase price of $103.50 per share with a group of investors. Concurrently in a private placement, for each share of common stock purchased by each investor, such investor received from the Company an unregistered warrant to purchase three quarters of a share of common stock (the "2016 Private Placement Warrants"). Initially, the 2016 Private Placement Warrants had an exercise price of $135.00 per share, were exercisable six months from the initial issuance date, and would expire five and a half years from the initial issuance date. The aggregate gross proceeds from the sale of the common stock and warrants was approximately $3.7 million, and the net proceeds after deduction of commissions, fees and expenses was approximately $3.2 million. In connection with this transaction, the Company issued to the placement agent warrants to purchase up to 1,804 shares of common stock sold in this offering (the "2017 Placement Agent Warrants" and, together with the 2016 Private Placement Warrants, the "September 2016 Warrants"). The 2016 Placement Agent Warrants have substantially the same terms as the 2016 Private Placement Warrants, except that initially, the 2016 Placement Agent Warrants had an exercise price of $129.375 per share and would expire five years from the initial issuance date. Initially, the September 2016 Warrants were accounted for as a liability and fair-valued at the issuance date. Out of the total gross proceeds, $1.6 million was allocated to the 2016 Private Placement Warrants based on their fair value, and the rest was allocated to the common stock and recorded in equity. Also, in connection with the transaction, the Company incurred cash-based transaction costs of approximately $0.5 million and non-cash transaction costs of $0.1 million related to the fair value of the 2016 Placement Agent Warrants. These costs were allocated between the warrant liability and equity based on their relative values at the issuance date. The transaction costs that were allocated to the warrant liability of approximately $0.3 million were expensed and included in other financing expenses on the consolidated statements of operations and the transaction costs of approximately $0.4 million related to the common stock were netted against the proceeds allocated to the common stock shares in equity. In connection with the April 2017 Financing, the Private Placement Warrants and the Placement Agent Warrants were amended pursuant to which, among other things, (i) the exercise price of the warrants was reduced to $46.50 per share (the exercise price of the warrants sold in the April 2017 Financing), (ii) the terms of the agreement were amended so that the shares cannot be cash settled under any circumstance, and (iii) the date upon which such warrants became exercisable was changed to the effective date of the Charter Amendment, or May 17, 2017 (the "April 2017 Warrant Amendment"). Based upon the amended terms of the agreement, the September 2016 Warrants were reclassified to stockholders' equity at the time of the April 2017 Warrant Amendment, or April 20, 2017. The fair value of the warrants on that date was $0.8 million, which resulted in a charge of $0.2 million to change in fair value of warrant liability on the consolidated statements of operations before reclassification to stockholders' equity during the second quarter of 2017. July 2016 Aspire Common Stock Purchase Agreement In July 2016, the Company and Aspire Capital entered into the Aspire Purchase Agreement, which provided that Aspire Capital was committed to purchase, if the Company chooses to sell and at the Company's discretion, an aggregate of up to $7.0 million of shares of the Company's common stock over the 24-month term of the Aspire Purchase Agreement. The Aspire Purchase Agreement could have been terminated at any time by the Company by delivering notice to Aspire Capital. On the Aspire Closing Date, the Company delivered to Aspire Capital a commitment fee of 5,063 shares of the Company's common stock at a value of $0.6 million, in consideration for Aspire Capital entering into the Aspire Purchase Agreement. Additionally, on the Aspire Closing Date, the Company sold 8,439 shares of the Company's common stock to Aspire Capital for proceeds of $1.0 million. In connection with the transaction, the Company incurred cash transaction costs of approximately $0.1 million, which were netted against the proceeds in equity. On any business day during the 24-month term of the Aspire Purchase Agreement, the Company has the right, in its sole discretion, to present Aspire Capital with a purchase notice (each, a "Purchase Notice") directing Aspire Capital to purchase up to 333 shares of the Company's common stock per business day, subject to certain limitations. The Company and Aspire Capital could have mutually agreed to increase the number of shares that could have been sold pursuant to a Purchase Notice to as much as an additional 6,667 shares of the Company's common stock per business day. The purchase price per share of the Company's common stock sold to Aspire Capital pursuant to a Purchase Notice was equal to the lower of (i) the lowest sales price of the Company's common stock on the purchase date or (ii) the average of the lowest three closing sales prices of the Company's common stock for the twelve business days prior to the purchase date. Under the Aspire Purchase Agreement, the Company and Aspire Capital shall not effect any sales on any purchase date where the closing sale price of the Company's common stock is less than $30.00. Additionally, on any date on which (i) the Company submitted a Purchase Notice to Aspire Capital for at least 333 shares of the Company's common stock and (ii) the last closing trade price for the Company's common stock was higher than $90.00, the Company has the right, in its sole discretion, to present Aspire Capital with a volume-weighted average price purchase notice (each, a "VWAP Purchase Notice") directing Aspire Capital to purchase an amount of the Company's common stock equal to up to 30% of the aggregate shares of the Company's common stock traded on the next business day (the "VWAP Purchase Date"), subject to certain limitations. The purchase price per share of the Company's common stock sold to Aspire Capital pursuant to a VWAP Purchase Notice shall be the lesser of (i) the closing sale price of the Company's common stock on the VWAP Purchase Date or (ii) 97% of the volume weighted average price of the Company's common stock traded on the VWAP Purchase Date, subject to certain limitations. The Company also entered into a registration rights agreement with Aspire Capital, in which the Company agreed to file one or more registration statements, as permissible and necessary to register, under the Securities Act of 1933, as amended, the sale of the shares of the Company's common stock that have been and may be issued to Aspire Capital under the Purchase Agreement. Pursuant to the Aspire Purchase Agreement, in no case could the Company issue more than 40,000 shares of the Company's common stock (which is equal to approximately 19.99% of the Company's common stock outstanding on the Aspire Closing Date) to Aspire Capital unless (i) the average price paid for all shares issued under the Aspire Purchase Agreement is at least $114.60 per share (a price equal to the most recent consolidated closing bid price of the Company's common stock prior to the execution of the Aspire Purchase Agreement) or (ii) the Company received stockholder approval to issue more shares to Aspire Capital. Since the inception of the Aspire Purchase Agreement through its termination, the Company has issued a total of 16,667 shares for gross proceeds of $1.2 million. Upon its termination, all of the reserve was available under the committed equity financing facility since the Company's stock price was above $3.00, subject to SEC limitations under the Form S-3 Registration Statement. However, in connection with the September 2016, April 2017 and April 2018 Financings, the Company agreed to not make any further sales under the Aspire Purchase Agreement for a period of twelve months following the date of each financing. January 2016 Financing In January 2016, the Company entered into subscription agreements with certain purchasers pursuant to which it agreed to sell an aggregate of 37,879 shares of its common stock and warrants to purchase up to an additional 18,939 shares of its common stock to the purchasers for an aggregate offering price of $10.0 million, to take place in separate closings (the "January 2016 Financing"). Each share of common stock was sold at a price of $264.00 and included one half of a warrant to purchase a share of common stock. During the first closing in January 2016, the Company sold an aggregate of 8,428 shares and warrants to purchase up to 4,214 shares of common stock for gross proceeds of $2.2 million. The remaining shares and warrants were sold in a subsequent closing in March 2016 for gross proceeds of $7.8 million following stockholder approval at a special meeting on March 2, 2016. The aggregate net proceeds, after deduction of fees and expenses of approximately $0.4 million, were approximately $9.6 million. The warrants issued in connection with the January 2016 financing (the "January 2016 Warrants") occurred in separate closings in January 2016 and March 2016 and gave rights to purchase up to 18,939 total shares of the Company's common stock at an exercise price of $264.00 per share. The total initial $4.8 million fair value of the warrants on their respective closing dates was determined using the Black-Scholes option pricing model and was recorded as the initial carrying value of the common stock warrant liabilities. The warrants issued in January 2016 and March 2016 were initially valued using assumptions of expected terms of 7.0 years, volatilities of 101.9% and 99.4%, respectively, annual rate of dividends of 0.0%, and risk-free interest rates of 1.6% and 1.4%, respectively. Fees and expenses of approximately $0.2 million were allocated to the warrant liability and expensed in Other Financing Costs. The remaining expenses were netted against the proceeds allocated to the common stock shares in equity. The fair value of these warrants is remeasured at each financial reporting period with any changes in fair value recognized as a change in fair value of warrant liability in the accompanying consolidated statements of operations. These warrants became exercisable in July 2016 and September 2016 and have expiration dates of January 2023 and March 2023, respectively. Pursuant to the January 2016 financing, the exercise price of warrants issued in connection with a financing in February 2015 were reduced from $546.00 per share to $264.00 per share. The modification to these warrants resulted in a charge to other financing costs of approximately $0.7 million in 2016. The exercise price of these warrants was further reduced in March 2018. See above for details. Warrants A summary of warrant activity during the year ended December 31, 2018 is as follows (share amounts in thousands): Weighted Common Shares Average Issuable upon Exercise Exercise Price Outstanding at December 31, 2017 236 $ 117.30 Issued 342 $ 12.30 Exercised (35) $ 44.40 Cancelled (107) $ 119.70 Outstanding as of December 31, 2018 437 $ 20.70 Exercisable as of December 31, 2018 225 $ 30.30 The following table shows the number of outstanding warrants by exercise price and date of expiration as of December 31, 2018 (share amounts in thousands): Shares Issuable Upon Exercise Exercise Price Expiration Date 13 $ 18.00 March 2020 8 $ 52.50 April 2022 82 $ 46.50 May 2022 11 $ 12.60 January 2023 3 $ 21.30 January 2023 11 $ 12.60 March 2023 4 $ 21.30 March 2023 12 $ 18.90 March 2023 80 $ 15.00 May 2023 8 $ 10.14 March 2024 115 $ 9.00 March 2024 89 $ 12.00 March 2024 1 $ 387.00 October 2024 1 $ 492.00 July 2025 437

Equity Compensation Plans

Equity Compensation Plans	12 Months Ended
	Dec. 31, 2018
Warrants Expiring March 2023, Tranche 3 [Member]
Equity Compensation Plans	8. EQUITY COMPENSATION PLANS As of December 31, 2018, the Company has one share-based compensation plan, the 2012 Stock Long Term Incentive Plan (the "2012 Plan"), which provides for the issuance of incentive and non-incentive stock options, restricted and unrestricted stock awards, stock unit awards and stock appreciation rights. Options and restricted stock units granted generally vest over a period of one to four years and have a maximum term of ten years from the date of grant. As of December 31, 2018, an aggregate of 67,731 shares of common stock were authorized under the 2012 Plan, of which 10,872 common shares were available for future grants. Stock Options A summary of stock option activity during the year ended December 31, 2018 is as follows (share amounts in thousands): Weighted Weighted Total Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Shares Price Life (in years) Value Outstanding as of December 31, 2017 12 $ 521.10 6.7 $ - Granted 23 63.30 Exercised - - Cancelled (6) 183.90 - - Outstanding as of December 31, 2018 29 $ 230.10 7.8 $ - Vested and expected to vest as of December 31, 2018 29 $ 230.10 7.8 $ - Exercisable as of December 31, 2018 15 $ 375.00 6.8 $ - As of December 31, 2018 and 2017, there were 15,076 and 9,777 options exercisable, respectively. There were no options exercised during either of the years ended December 31, 2018 and 2017. The total fair value of options vested during the years ended December 31, 2018 and 2017 was $1.0 million and $0.8 million, respectively. Restricted Stock Units A summary of restricted stock unit activity during the year ended December 31, 2018 is as follows: Weighted Number of Average Grant Shares Date Fair Value Nonvested as of December 31, 2017 24 $ 47.10 Granted - $ - Vested (14) $ 49.50 Forfeited (1) $ 39.60 Nonvested as of December 31, 2018 9 $ 43.80 The total fair value of awards vested during the years ended December 31, 2018 and 2017 was $0.3 million and $0.4 million for each year. respectively. Share-Based Compensation The value of restricted stock unit grants is calculated based upon the closing stock price of the Company's common stock on the date of the grant. For stock options granted to employees and directors, the Company recognizes compensation expense based on the grant-date fair value over the requisite service period of the awards, which is the vesting period. The Company estimates the fair value of each option award on the date of grant using the Black-Scholes option pricing model. The following table presents the weighted average assumptions used by the Company to estimate the fair value of stock option grants using the Black-Scholes option-pricing model, as well as the resulting weighted average fair values at their issuance dates during the year ended December 31, 2018. No stock options were granted during the year ended December 31, 2017. 2018 Risk-free interest rate 2.3%-2.3% Volatility 98%-105% Dividend yield -- % Expected term 5-6.08 years Forfeiture rate 11.33% Weighted average fair value $ 49.88 Expected Volatility. Expected Term Risk-Free Interest Rate Dividend Yield Pre-Vesting Forfeitures As of December 31, 2018, there was $0.6 million in unrecognized compensation cost related to non-vested stock options expected to be recognized over a weighted average period of 2.7 years. As of December 31, 2018, there was $0.06 million in unrecognized compensation cost related to non-vested restricted stock units expected to be recognized over a weighted average period of 0.08 year. In addition, the Company has $0 in unrecognized compensation cost related to performance restricted stock units. The Company records expense related to its performance RSUs based on the probability of occurrence, which is reassessed each quarter. The following table summarizes the total stock-based compensation expense resulting from share-based awards recorded in the Company's consolidated statements of operations (in thousands): Year Ended December 31, 2018 2017 Research and development $ 336 $ 227 General and administrative 965 911 $ 1,301 $ 1,138

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2018
Related Party Transactions [Abstract]
Related Party Transactions	9. RELATED PARTY TRANSACTIONS The Company had the following related party transaction for 2018: IRRAS AB IRRAS AB ("IRRAS") is a commercial stage medical technology company of which a current director of the Company, Kleanthis G. Xanthopoulos, Ph.D., is currently the President, Chief Executive Officer and director. In January 2018, the Company and IRRAS entered into a Sublease, pursuant to which the Company subleased to IRRAS excess capacity in its corporate headquarters. The sublease has a term of two years and aggregate payments due to the Company of approximately $0.3 million. On October 30, 2018, the Company and IRRAS entered into an amended and restated sublease, commencing January 1, 2019, pursuant to which the Company agreed to sublease to IRRAS the remainder of its current corporate headquarters (the "IRRAS Restated Sublease"), which satisfied a closing condition related to the merger. The IRRAS Restated Sublease has a term of one year and provides for aggregate payments due to the Company of approximately $0.4 million, which approximate fair value.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2018
Warrants Expiring March 2024 [Member]
Income Taxes	10. INCOME TAXES The Company has incurred losses since inception, which have generated net operating loss carryforwards and capital loss carryforwards of approximately $118.4 million and $9.8 million for federal and California income tax purposes, respectively. These carryforwards are available to offset future taxable income and expire beginning in 2019 through 2037 for federal income tax purposes and beginning in 2030 through 2033 for California income tax purposes. Also, Federal net operating loss carryforwards that were generated in 2018 have an indefinite carryforward period. In addition, the Company has research and development tax credit carryforwards for federal and state income tax purposes as of December 31, 2018 of $1.8 million and $1.0 million, respectively. The federal credits will begin to expire in 2019 unless utilized and the state credits have an indefinite life. Utilization of the loss carryforwards may be subject to a substantial annual limitation due to ownership change limitations that may have occurred or that could occur in the future, as required under Internal Revenue Code Section 382 ("Section 382"), as well as similar state and foreign provisions. These ownership changes may limit the amount of loss carryforwards that can be utilized annually to offset future taxable income. In general, an "ownership change" as defined by Section 382 results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders or public groups. Since the Company's formation, the Company has raised capital through the issuance of capital stock on several occasions which, combined with the purchasing stockholders' subsequent disposition of those shares, likely resulted in such an ownership change, or could result in an ownership change in the future upon subsequent disposition. During the first quarter of 2017, the Company completed a study to assess whether an ownership change occurred and determined that there have been multiple ownership changes since the Company's formation. As a result, utilization of the loss carryforwards are subject to an annual limitation under Section 382, which was determined by first multiplying the value of the Company's stock at the time of the ownership change by the applicable long-term, tax-exempt rate. These limitations resulted in the expiration of the majority of the Company's loss carryforwards. These loss carryforwards that have expired due to these limitations have been removed from deferred tax assets with a corresponding reduction of the valuation allowance with no net effect on income tax expense or the effective tax rate. Despite the assessment completed during the first quarter of 2017, additional ownership changes may have occurred subsequent to the completion of the study, which would continue to limit utilization of any future loss carryforwards including as a result of the Merger which occurred subsequent to the Company's year end. During the first quarter of 2017, the Company completed a study to assess whether an ownership change occurred and determined that there have been multiple ownership changes since the Company's formation. As a result, utilization of the loss carryforwards are subject to an annual limitation under Section 382, which was determined by first multiplying the value of the Company's stock at the time of the ownership change by the applicable long-term, tax-exempt rate. These limitations resulted in the expiration of the majority of the Company's loss carryforwards. These loss carryforwards that have expired due to these limitations have been removed from deferred tax assets with a corresponding reduction of the valuation allowance with no net effect on income tax expense or the effective tax rate. Despite the assessment completed during the first quarter of 2017, additional ownership changes may have occurred subsequent to the completion of the study, which would continue to limit utilization of any future loss carryforwards. Deferred tax assets consist of the following (in thousands): December 31, 2018 2017 Net operating tax loss and capital loss carryforwards $ 25,549 $ 23,463 Capitalized research and development costs 4,194 4,620 Research and development tax credits 1,937 1,923 Other accruals and reserves 494 721 Basis of intangible assets 3,136 3,658 Total deferred tax asset 35,310 34,385 Less valuation allowance (35,310) (34,385) Net deferred tax asset $ - $ - The federal net operating loss carryforwards and tax credit carryforwards resulted in a noncurrent deferred tax asset as of December 31, 2018 and 2017 of approximately $27.5 million and $25.4 million, respectively. In consideration of the Company's accumulated losses and the uncertainty of its ability to utilize this deferred tax asset in the future, the Company has recorded a full valuation allowance as of such dates. The Company follows the provisions of income tax guidance which provides recognition criteria and a related measurement model for uncertain tax positions taken or expected to be taken in income tax returns. The guidance requires that a position taken or expected to be taken in a tax return be recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities. Tax positions that meet the more likely than not threshold are then measured using a probability weighted approach recognizing the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement. The Company's Federal income tax returns for 2015 to 2018 are still open and subject to audit. In addition, net operating losses and capital losses arising from prior years are also subject to examination at the time they are utilized in future years. Unrecognized tax benefits, if recognized, would have no effect on the Company's effective tax rate. The Company's policy is to recognize interest and penalties related to income tax matters in income tax expense. For the years ended December 31, 2018 and 2017, the Company has not recorded any interest or penalties related to income tax matters. The Company does not foresee any material changes to unrecognized tax benefits within the next twelve months. A reconciliation of the Company's unrecognized tax benefits for the years ended December 31, 2018 and 2017, are as follows (in thousands): Year Ended December 31, 2018 2017 Beginning balance $ 713 $ 3,047 Change in current period positions 13 34 Change in prior period positions (8) (2,368) Ending balance $ 718 $ 713 The reconciliation of income taxes computed using the statutory United States income tax rate and the provision (benefit) for income taxes for the years ended December 31, 2018 and 2017, are as follows: Year Ended December 31, 2018 2017 Federal statutory tax rate (21) % (34) % Change in rate - % 165 % Valuation allowance 10 % (360) % Deferred tax true-ups 5 % 227 % Revaluation of warrants - % 2 % Permanent differences 7 % 1 % Tax credits (1) % (1) % Income tax expense - % - % US Tax Reform On December 22, 2017, the 2017 Tax Cuts and Jobs Act (Tax Act) was enacted into law and the new legislation contains several key tax provisions that affected the Company, including a reduction of the corporate income tax rate to 21% effective January 1, 2018, among others. The Company is required to recognize the effect of the tax law changes in the period of enactment, such as determining the transition tax, remeasuring the Company's U.S. deferred tax assets and liabilities, as well as reassessing the net realizability of the Company's deferred tax assets and liabilities. In December 2017, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (SAB 118), which allowed the Company to record provisional amounts during a measurement period not to extend beyond one year of the enactment date. As a result, the Company previously provided a provisional estimate of the effect of the Tax Act in the Company's financial statements. In the fourth quarter of 2018, the Company completed its analysis to determine the effect of the Tax Act and recorded no material adjustments as of December 31, 2018.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. COMMITMENTS AND CONTINGENCIES Operating Leases In December 2011, the Company entered into a five-year lease agreement for its headquarters in San Diego, California expiring December 31, 2016. In December 2015, the Company amended the lease agreement to extend the term through December 31, 2020. The Company has an option to extend the lease an additional three years. The original lease term contained a base rent of approximately $24,000 per month with 3% annual escalations, plus a supplemental real estate tax and operating expense charge to be determined annually. The Company received a total of a six-month base rent abatement from the lease agreement and amendment. This abatement is recoverable by the landlord on a straight-line amortized basis over 60 months should the Company terminate the lease early for any reason. In 2018, the Company subleased excess capacity in its San Diego headquarters to a subtenant under a non-cancellable lease. The sublease has a term of two years and aggregate payments due to the Company of approximately $0.3 million. On October 30, 2018, the Company amended and restated its sublease, commencing January 1, 2019, pursuant to which the Company agreed to sublease the remainder of its San Diego headquarters, which satisfied a closing condition related to the merger. The amended and restated sublease has a term of one year and provides for aggregate payments due to the Company of approximately $0.4 million, which approximate fair value. For the years ended December 31, 2018 and 2017, rent expense totaled $0.3 million and $0.3 million, respectively. Future minimum rental payments under operating leases as of December 31, 2018 are as follows (in thousands): 2019 $ 374 2020 32 Total $ 406 Certain employees have agreements that provide for severance compensation in the event of termination or a change in control. These agreements can provide for a severance payment of up to 18 months of base salary and bonus in effect at the time of termination and continued health benefits at the Company's cost for up to 18 months. Litigation The Company may be a party to certain other litigation that is either judged to be not material or that arises in the ordinary course of business from time to time. The Company intends to vigorously defend its interests in these matters and does not expect that the resolution of these matters will have a material adverse effect on its business, financial condition or results of operations. However, due to the uncertainties inherent in litigation, no assurance can be given as to the outcome of these proceedings. A complaint was filed in the Supreme Court of the State of New York by Laboratoires Majorelle SAS and Majorelle International SARL ("Majorelle") on July 25, 2017 naming Apricus Biosciences, Inc., NexMed (U.S.A.), Inc. and Ferring as defendants. The complaint sought a declaratory judgment that a non-compete provision in a license agreement between the Company and Majorelle, dated November 12, 2013, was unenforceable and made other claims relating to invalidity of the Company's assignment of the license agreement to Ferring under the Ferring Asset Purchase Agreement. The complaint also alleged breach of contract, fraudulent inducement, misrepresentation and unjust enrichment relating to a separate supply agreement between the Company and Majorelle. In addition to declaratory relief, Majorelle sought damages in excess of $1.0 million, disgorgement of profits and attorney's fees. On August 30, 2017, the Company and NexMed removed the case to federal district court in the Southern District of New York. Majorelle filed an amended complaint on October 16, 2017. The Company filed a motion to dismiss all claims in the amended complaint on December 5, 2017. The Company filed a motion to dismiss all claims in the amended complaint on December 5, 2017. On September 21, 2018, the Court granted the Company's motion to dismiss Majorelle's federal antitrust claim and dismissed the entire case.

Subsequent Event

Subsequent Event	12 Months Ended
	Dec. 31, 2018
Subsequent Events [Abstract]
Subsequent Event	12. SUBSEQUENT EVENT Merger On January 24, 2019, the Company completed the Merger with STI, pursuant to which Merger Sub merged with and into STI, with STI surviving as the Company's wholly-owned subsidiary. See note 2 to the consolidated financial statements above for additional information on the Merger. Severance The Company paid approximately $1.8 million in January 2019 pursuant to certain employment agreements that triggered upon the completion of the Merger with STI.

Organization and Summary of S_2

Organization and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The accompanying consolidated financial statements have been prepared on a basis which assumes the Company is a going concern and that contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company had an accumulated deficit of approximately $325.2 million as of December 31, 2018. As of December 31, 2018, the Company had a cash balance of approximately $3.6 million. The Company also reported negative cash flows from operations of $8.1 million for the year ended December 31, 2018. The Company's history and other factors raise substantial doubt about the Company's ability to continue as a going concern. The Company has principally been financed through the sale of its common stock and other equity securities, debt financings, up-front payments received from commercial partners for the Company's products under development, and through the sale of assets. The accompanying consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern. The Company's future liquidity and capital funding requirements will depend on numerous factors, including: its ability to raise additional funds to finance its operations; its ability to maintain compliance with the listing requirements of The Nasdaq Capital Market ("Nasdaq"); the outcome, costs and timing of clinical trial results for the Company's current or future product candidates; litigation expenses and the extent and amount of any indemnification claims; the emergence and effect of competing or complementary products; its ability to maintain, expand and defend the scope of its intellectual property portfolio, including the amount and timing of any payments the Company may be required to make, or that it may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights; its ability to retain its current employees and the need and ability to hire additional management and scientific and medical personnel; the terms and timing of any collaborative, licensing or other arrangements that it has or may establish; the trading price of its common stock; and its ability to increase the number of authorized shares outstanding to facilitate future financing events. The Company will likely need to raise substantial additional funds through one or more of the following: issuance of additional debt or equity, or the completion of a licensing transaction for one or more of the Company's pipeline assets. If the Company is unable to maintain sufficient financial resources, its business, financial condition and results of operations will be materially and adversely affected. This could affect future development and business activities and potential future clinical studies and/or other future ventures. Failure to obtain additional equity or debt financing will have a material, adverse impact on the Company's business operations. There can be no assurance that the Company will be able to obtain the needed financing on acceptable terms or at all. Additionally, equity or debt financings will likely have a dilutive effect on the holdings of the Company's existing stockholders. On April 10, 2018, the Company was notified that, based on the previous thirty consecutive business days, the Company's common stock no longer met the minimum $1.00 bid price per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Requirement") and at that time, the Company was provided 180 calendar days, or until October 8, 2018, to regain compliance. On October 9, 2018, the Company received a letter from Nasdaq indicating that the Company's common stock has not regained compliance with the Bid Price Requirement. However, in accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an additional 180 calendar day period, or until April 8, 2019, to regain compliance. The Nasdaq Staff's determination that the Company is eligible for additional time is based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market, with the exception of the Bid Price Requirement, and the Company's written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If at any time before April 8, 2019, the closing bid price of the Company's common stock is at least $1.00 per share for a minimum of ten consecutive business days, the Nasdaq Staff will provide written confirmation of compliance with Rule 5550(a) and this matter will be closed. The Nasdaq letter has no immediate effect on the listing or trading of the Company's common stock and the common stock will continue to trade on The Nasdaq Capital Market under the symbol "APRI." The Company intends to monitor the bid price of its common stock and consider available options if its common stock does not trade at a level likely to result in the Company regaining compliance with the Bid Price Requirement by April 8, 2019. If compliance cannot be demonstrated by April 8, 2019, the Nasdaq Staff will provide written notification that the Company's common stock will be delisted. At that time, the Company may appeal the Nasdaq Staff's determination to a Hearings Panel. On February 7, 2019, the Company was notified by the Nasdaq Staff that for more than the last 10 consecutive business days, from January 24, 2019 through February 6, 2019, the closing bid price of the Company's common stock had been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2), and this matter is now closed.
Merger	Merger On January 24, 2019, the Company completed a reverse merger transaction (the "Merger") with Seelos Therapeutics, Inc., a Delaware corporation (now known as Seelos Corporation) ("STI"). Upon completion of the Merger, the Company changed its name to Seelos Therapeutics, Inc. and will focus on the development and commercialization of CNS therapeutics with known mechanisms of action in areas with a highly unmet medical need. On January 23, 2019, in connection with, and prior to the completion of, the Merger, we effected a reverse stock split of our common stock at a ratio of 1-for-30 (the "Reverse Stock Split"). Unless otherwise noted, references to share amounts, and other information have been adjusted to reflect the Reverse Stock Split. Shares of the Company's common stock commenced trading on the Nasdaq Capital Market under the ticker symbol "SEEL" as of market open on January 24, 2019. The Company's previous ticker symbol was "APRI". See note 2 below for more information regarding the Merger. These financial statements are of Apricus Biosciences, Inc. prior to the Merger because the Merger was consummated after the period covered by these financial statements. Accordingly, the historical financial information included in this Annual Report on Form 10-K, unless otherwise indicated or as the context otherwise requires, is that of Apricus Biosciences, Inc. prior to the Merger. The Company plans on developing its clinical and regulatory strategy with its internal research and development team with a view toward prioritizing market introduction as quickly as possible. The Company's lead programs following the completion of the merger are SLS-002 for the potential treatment of suicidality in post-traumatic stress disorder ("PTSD"), and in major depressive disorder, SLS-005 for Sanfilippo syndrome and SLS-006 for the potential treatment of Parkinson's disease. Additionally, the Company is developing several preclinical programs, most of which have well-defined mechanisms of action, including: SLS-008 targeted at chronic inflammation in asthma and orphan indications such as pediatric esophagitis, SLS-010, in narcolepsy and related disorders and SLS-012, an injectable therapy for post-operative pain management.
Use of Estimates	Use of Estimates The preparation of these consolidated financial statements in conformity with generally accepted accounting principles ("GAAP") requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. The Company's most significant estimates relate to the valuation of stock-based compensation, the valuation of its warrant liabilities, the impairment of long-lived assets and valuation allowances for the Company's deferred tax assets. The Company's actual results may differ from these estimates under different assumptions or conditions.
Warrant Liabilities	Warrant Liabilities Prior to 2018, the Company's 2015 and 2016 Warrants were classified as liabilities in the accompanying consolidated 2017 balance sheet as they contained provisions that were considered outside of the Company's control, such as requiring the Company to maintain active registration of the shares underlying such warrants. The 2015 and 2016 Warrants were recorded at fair value using the Black-Scholes option pricing model. The fair value of these warrants was re-measured at each financial reporting period with any changes in fair value being recognized as a component of other income (expense) in the accompanying consolidated statements of operations for 2017. In March 2018, the Company entered into the March 2018 Warrant Amendment with the holders of its 2015 and 2016 Warrants, which amended the terms so that in no circumstances may the 2015 and 2016 Warrants be net-cash settled. As a result, the fair value of the 2015 and 2016 Warrants at the date of the modification were reclassified to equity. All of the Company's outstanding warrants, other than the Pre-Merger Warrants, have similar terms whereas under no circumstance may the warrants be net-cash settled. As such, all warrants are equity-classified. See note 7 for further details.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company’s financial instruments consist principally of accounts payable, accrued expenses, and historically, its Credit Facility with the Lenders. The carrying amounts of financial instruments such as accounts receivable, accounts payable and accrued expenses approximate their related fair values due to the short-term nature of these instruments.
Property and Equipment	Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Depreciation is provided on a straight-line basis over the estimated useful lives of the assets. The Company estimates useful lives as follows: Machinery and equipment: three to five years Furniture and fixtures: ten years Computer software: five years Amortization of leasehold improvements and capital lease equipment is provided on a straight-line basis over the shorter of their estimated useful lives or the lease term. The costs of additions and betterments are capitalized, and repairs and maintenance costs are charged to operations in the periods incurred (see note 5 for further details).
Leases	Leases Leases are reviewed and classified as capital or operating at their inception. Historically, the Company recorded rent expense associated with its operating lease on a straight-line basis over the term of the lease. The difference between rent payments and straight-line rent expense was recorded as deferred rent in accrued liabilities. In January 2018, the Company subleased a portion of its office space. During the first quarter of 2018, the Company recorded a liability for the present value of the remaining lease due, offset by the sublease income reasonably expected over the remaining term of the lease.
Fair Value Measurements	Fair Value Measurements The Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established by accounting guidance and prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The Company's common stock warrant liabilities were measured and disclosed at fair value on a recurring basis, and were classified within the Level 3 designation. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability. In March 2018, the Company entered into the March 2018 Warrant Amendment with the holders of its 2015 and 2016 Warrants, which amended the terms so that in no circumstances may the 2015 and 2016 Warrants be net-cash settled. As a result, the Company's 2015 and 2016 Warrants were reclassified from liabilities to equity during the first quarter of 2018 and will no longer be measured at fair value on a recurring basis.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss is recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than it's carrying amount. If such assets are considered impaired, the amount of the impairment loss recognized is measured as the amount by which the carrying value of the asset exceeds the fair value of the asset, fair value being determined based upon future cash flows or appraised values, depending on the nature of the asset. The Company recognized no impairment losses during either of the periods presented within its financial statements.
Research and Development	Research and Development Research and development costs are expensed as incurred and include the cost of compensation and related expenses, as well as expenses for third parties who conduct research and development on the Company's behalf, pursuant to development and consulting agreements in place.
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. The Company also follows the provisions of accounting for uncertainty in income taxes which prescribes a model for the recognition and measurement of a tax position taken or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure and transition.
Income (Loss) Per Common Share	Income (Loss) Per Common Share Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the same period. Diluted net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares and common equivalent shares outstanding during the same period. Common equivalent shares may be related to stock options, restricted stock units, or warrants. The Company excludes common stock equivalents from the calculation of diluted net income (loss) per share when the effect is anti-dilutive.
Stock-Based Compensation	Stock-Based Compensation The estimated grant date fair value of stock options granted to employees and directors is calculated based upon the closing stock price of the Company's common stock on the date of the grant and recognized as stock-based compensation expense over the expected service period, which is typically approximated by the vesting period. The Company estimates the fair value of each option award on the date of grant using the Black-Scholes option pricing model. The value of restricted stock unit grants is calculated based upon the closing stock price of the Company's common stock on the date of the grant.
Segment Information	Segment Information The Company operates under one segment which develops pharmaceutical products.
Geographic Information	Geographic Information Revenues (included in discontinued operations) by geographic area for the Company's operations are as follows (in thousands): Year Ended December 31, 2018 2017 Europe (1)(2) $ - $ 364 Canada (1) - 142 Other (1)(2) - 5 $ - $ 511 (1) As a result of the Ferring Asset Purchase Agreement, all revenues have been reflected as discontinued operations in the statement of operations for all periods presented. All of the Company's net long-lived assets were located in the United States for each of the years ended December 31, 2018 and 2017, respectively.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. ASU 2016-12, Revenue from Contracts with Customers In February 2016, the FASB issued ASU 2016-2, Leases

Organization and Summary of S_3

Organization and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Schedule of Fair Value Hierarchy for Warrant Liabilities	The following table presents the Company's fair value hierarchy for its warrant liabilities measured at fair value on a recurring basis (in thousands) as of December 31, 2017: Quoted Market Significant Prices for Other Significant Identical Observable Unobservable Assets Inputs Inputs Warrant liabilities (Level 1) (Level 2) (Level 3) Total Balance as of December 31, 2017 $ - $ - $ 694 $ 694
Summary of Fair Value Measurements Valuation Assumptions	The following assumptions were used in determining the fair value of the common stock warrant liabilities valued using the Black-Scholes option pricing model as of December 31, 2017: December 31, 2017 Risk-free interest rate 2.2%-2.2% Volatility 89%-89.41% Dividend yield - % Expected term 5.04-5.17 Weighted average fair value $ 24.00
Schedule of Fair Value Level 3 Reconciliation	The following table is a reconciliation for the common stock warrant liabilities measured at fair value using Level 3 unobservable inputs (in thousands): Warrant liabilities Balance as of December 31, 2017 $ 694 Change in fair value measurement of warrant liability (222) Warrant liability reclassified to stockholders' equity (472) Balance as of December 31, 2018 $ -
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following securities that could potentially decrease net income (loss) per share in the future are not included in the determination of diluted income (loss) per share as their effect is anti-dilutive (in thousands): Year Ended December 31, 2018 2017 Outstanding stock options 29 12 Outstanding warrants 437 236 Restricted stock units 9 24 475 272
Summary of Revenues by Geographic Area	Revenues (included in discontinued operations) by geographic area for the Company's operations are as follows (in thousands): Year Ended December 31, 2018 2017 Europe (1)(2) $ - $ 364 Canada (1) - 142 Other (1)(2) - 5 $ - $ 511 (1) As a result of the Ferring Asset Purchase Agreement, all revenues have been reflected as discontinued operations in the statement of operations for all periods presented.

Ferring Asset Purchase Agreem_2

Ferring Asset Purchase Agreement and Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2018
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Gain on Sale of Purchased Assets	The total gain on sale of the Purchased Assets to Ferring consisted of the following: Upfront payment received $ 11,500 Transition services payments 500 Payment received for inventory 709 Total proceeds from sale $ 12,709 Carrying value of assets sold in sale (1,578) Liabilities transferred upon sale 1,186 Total gain on sale of Purchased Assets $ 12,317
Schedule of Operating Results of Discontinued Operations	The operating results of the Company's discontinued operations are as follows (in thousands): Year Ended December 31, 2018 2017 Product sales $ - $ 143 Royalty revenue - 368 License fee revenue - - Cost of goods sold (24) (74) Cost of Sandoz rights - (10) Operating expenses - (658) Other expense - (16) Gain on sale - 12,317 (Loss) income from discontinued operations $ (24) $ 12,070

Other Financial Information (Ta

Other Financial Information (Tables)	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Property and Equipment	Property and equipment are comprised of the following (in thousands): December 31, 2018 2017 Leasehold improvements $ 20 $ 20 Machinery and equipment 270 270 Capital lease equipment 76 76 Computer software 130 130 Furniture and fixtures 25 25 Total property and equipment 521 521 Less: accumulated depreciation and amortization (483) (442) Property and equipment, net $ 38 $ 79
Schedule of Accrued Expenses	Accrued Expenses Accrued expenses are comprised of the following (in thousands): December 31, 2018 2017 Professional fees $ 548 $ 575 Outside research and development services 4 61 Other 92 14 Accrued expenses, net $ 644 $ 650
Schedule of Other Long Term Liabilities	Other long term liabilities are comprised of the following (in thousands): December 31, 2018 2017 Deferred rent $ 4 $ 46 Security deposit 12 12 Other long term liabilities, net $ 16 $ 58

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Summary of Warrant Activity	A summary of warrant activity during the year ended December 31, 2018 is as follows (share amounts in thousands): Weighted Common Shares Average Issuable upon Exercise Exercise Price Outstanding at December 31, 2017 236 $ 117.30 Issued 342 $ 12.30 Exercised (35) $ 44.40 Cancelled (107) $ 119.70 Outstanding as of December 31, 2018 437 $ 20.70 Exercisable as of December 31, 2018 225 $ 30.30 The following table shows the number of outstanding warrants by exercise price and date of expiration as of December 31, 2018 (share amounts in thousands): Shares Issuable Upon Exercise Exercise Price Expiration Date 13 $ 18.00 March 2020 8 $ 52.50 April 2022 82 $ 46.50 May 2022 11 $ 12.60 January 2023 3 $ 21.30 January 2023 11 $ 12.60 March 2023 4 $ 21.30 March 2023 12 $ 18.90 March 2023 80 $ 15.00 May 2023 8 $ 10.14 March 2024 115 $ 9.00 March 2024 89 $ 12.00 March 2024 1 $ 387.00 October 2024 1 $ 492.00 July 2025 437

Equity Compensation Plans (Tabl

Equity Compensation Plans (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Stock Option Activity	A summary of stock option activity during the year ended December 31, 2018 is as follows (share amounts in thousands): Weighted Weighted Total Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Shares Price Life (in years) Value Outstanding as of December 31, 2017 12 $ 521.10 6.7 $ - Granted 23 63.30 Exercised - - Cancelled (6) 183.90 - - Outstanding as of December 31, 2018 29 $ 230.10 7.8 $ - Vested and expected to vest as of December 31, 2018 29 $ 230.10 7.8 $ - Exercisable as of December 31, 2018 15 $ 375.00 6.8 $ -
Schedule of Restricted Stock Units Activity	A summary of restricted stock unit activity during the year ended December 31, 2018 is as follows: Weighted Number of Average Grant Shares Date Fair Value Nonvested as of December 31, 2017 24 $ 47.10 Granted - $ - Vested (14) $ 49.50 Forfeited (1) $ 39.60 Nonvested as of December 31, 2018 9 $ 43.80
Schedule of Valuation Assumptions for Stock Options	The following table presents the weighted average assumptions used by the Company to estimate the fair value of stock option grants using the Black-Scholes option-pricing model, as well as the resulting weighted average fair values at their issuance dates during the year ended December 31, 2018. No stock options were granted during the year ended December 31, 2017. 2018 Risk-free interest rate 2.3%-2.3% Volatility 98%-105% Dividend yield -- % Expected term 5-6.08 years Forfeiture rate 11.33% Weighted average fair value $ 49.88
Schedule of Stock-Based Compensation Expense	The following table summarizes the total stock-based compensation expense resulting from share-based awards recorded in the Company's consolidated statements of operations (in thousands): Year Ended December 31, 2018 2017 Research and development $ 336 $ 227 General and administrative 965 911 $ 1,301 $ 1,138

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets	Deferred tax assets consist of the following (in thousands): December 31, 2018 2017 Net operating tax loss and capital loss carryforwards $ 25,549 $ 23,463 Capitalized research and development costs 4,194 4,620 Research and development tax credits 1,937 1,923 Other accruals and reserves 494 721 Basis of intangible assets 3,136 3,658 Total deferred tax asset 35,310 34,385 Less valuation allowance (35,310) (34,385) Net deferred tax asset $ - $ -
Reconciliation of Unrecognized Tax Benefits	A reconciliation of the Company's unrecognized tax benefits for the years ended December 31, 2018 and 2017, are as follows (in thousands): Year Ended December 31, 2018 2017 Beginning balance $ 713 $ 3,047 Change in current period positions 13 34 Change in prior period positions (8) (2,368) Ending balance $ 718 $ 713
Reconciliation of Income Tax Effective Rate	The reconciliation of income taxes computed using the statutory United States income tax rate and the provision (benefit) for income taxes for the years ended December 31, 2018 and 2017, are as follows: Year Ended December 31, 2018 2017 Federal statutory tax rate (21) % (34) % Change in rate - % 165 % Valuation allowance 10 % (360) % Deferred tax true-ups 5 % 227 % Revaluation of warrants - % 2 % Permanent differences 7 % 1 % Tax credits (1) % (1) % Income tax expense - % - %

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Future Minimum Rental Payments Under Operating Leases	Future minimum rental payments under operating leases as of December 31, 2018 are as follows (in thousands): 2019 $ 374 2020 32 Total $ 406

Organization and Summary of S_4

Organization and Summary of Significant Accounting Policies - Liquidity (Details) $ / shares in Units, $ in Thousands

Sep. 20, 2018USD ($)$ / sharesshares

Apr. 02, 2018USD ($)warrant$ / sharesshares

Sep. 10, 2017USD ($)$ / sharesshares

Apr. 26, 2017USD ($)$ / sharesshares

Jul. 05, 2016shares

Sep. 30, 2016USD ($)$ / sharesshares

Jan. 31, 2016shares

Dec. 31, 2018USD ($)$ / sharesshares

Dec. 31, 2017USD ($)shares

Sep. 30, 2018shares

Apr. 30, 2018$ / shares

Apr. 20, 2017$ / shares

Dec. 31, 2016USD ($)

Basis Of Presentation [Line Items]

Accumulated deficit | $

$ 325,229

$ 315,987

Working capital | $

4,100

Net loss | $

(9,242)

321

Net cash used in operating activities | $

(8,126)

(10,571)

Cash | $

3,579

6,331

Cash and cash equivalents | $

$ 3,579

$ 6,331

$ 2,087

Shares issuable upon exercise of warrants (in shares)

437,000

Common stock, authorized (in shares)

60,000,000

30,000,000

Maximum potential proceeds from divestiture | $

$ 12,700

Proceeds from sale of rights to Vitaros product line | $

11,500

Proceeds from sale of product related inventory | $

709

Payment recognized related to transition services | $

500

Repayments of debt | $

$ 6,600

Shelf registration statement, available amount | $

$ 95,200

Entity public float, primary public offerings of securities, threshold (less than) | $

$ 75,000

Percent of public float eligible to to be raised if under threshold (as a percent)

33.33%

September 2018 Financing [Member]

Basis Of Presentation [Line Items]

Net proceeds from sale of common stock and warrants after transaction costs | $

$ 1,100

September 2017 Financing [Member]

Basis Of Presentation [Line Items]

Net proceeds from sale of common stock and warrants after transaction costs | $

$ 3,100

April 2017 Financing [Member]

Basis Of Presentation [Line Items]

Sale of stock, price per share (in usd per share) | $ / shares

$ 1.40

September 2016 Financing [Member]

Basis Of Presentation [Line Items]

Net proceeds from sale of common stock and warrants after transaction costs | $

$ 3,200

Common Stock

Basis Of Presentation [Line Items]

Issuance of common stock (in shares)

8,428

Common Stock | September 2018 Financing [Member]

Basis Of Presentation [Line Items]

Issuance of common stock (in shares)

153,333

Shares issued, price per share (in usd per share) | $ / shares

$ 8.10

Common Stock | April 2018 Financing [Member]

Basis Of Presentation [Line Items]

Net proceeds from financing transaction | $

$ 2,900

Number of units sold in transaction (in shares)

7,100,000

Sale of stock, price per share (in usd per share) | $ / shares

$ 0.50

Common Stock | September 2017 Financing [Member]

Basis Of Presentation [Line Items]

Issuance of common stock (in shares)

2,136,614

Shares issued, price per share (in usd per share) | $ / shares

$ 1.73

Common Stock | April 2017 Financing [Member]

Basis Of Presentation [Line Items]

Net proceeds from financing transaction | $

$ 5,900

Number of securities called by each warrant (in shares)

0.75

Common Stock | September 2016 Financing [Member]

Basis Of Presentation [Line Items]

Issuance of common stock (in shares)

1,082,402

Shares issued, price per share (in usd per share) | $ / shares

$ 3.45

September 2018 Warrants, Tranche 1 [Member] | September 2018 Financing [Member]

Basis Of Presentation [Line Items]

Shares issuable upon exercise of warrants (in shares)

3,450,000

Warrant vesting period

6 months

Exercise price (in usd per share) | $ / shares

$ 0.30

September 2018 Warrants [Member] | September 2018 Financing [Member]

Basis Of Presentation [Line Items]

Warrant expiration period

5 years

September 2018 Warrants, Tranche 2 [Member] | September 2018 Financing [Member]

Basis Of Presentation [Line Items]

Shares issuable upon exercise of warrants (in shares)

2,677,160

Warrant vesting period

6 months

Exercise price (in usd per share) | $ / shares

$ 0.40

September 2018 Placement Agent Warrants [Member] | September 2018 Financing [Member]

Basis Of Presentation [Line Items]

Warrant vesting period

6 months

Exercise price (in usd per share) | $ / shares

$ 0.3375

Warrant expiration period

5 years

April 2018 Placement Agent Warrants [Member] | April 2018 Financing [Member]

Basis Of Presentation [Line Items]

Exercise price (in usd per share) | $ / shares

$ 0.625

Warrant expiration period

5 years

April 2018 Warrants [Member] | April 2018 Financing [Member]

Basis Of Presentation [Line Items]

Exercise price (in usd per share) | $ / shares

$ 0.50

Warrant expiration period

5 years

Number of warrants attached to each stock unit (in warrants) | warrant

1

Number of securities called by each warrant (in shares)

0.5

Warrants Expiring March 2020, Tranche 2

Basis Of Presentation [Line Items]

Shares issuable upon exercise of warrants (in shares)

13,000

Exercise price (in usd per share) | $ / shares

$ 18

Warrants Expiring March 2020, Tranche 2 | September 2017 Financing [Member]

Basis Of Presentation [Line Items]

Exercise price (in usd per share) | $ / shares

$ 2.16

$ 0.60

Warrant expiration period

2 years 6 months

Warrants Expiring March 2020, Tranche 1 [Member] | September 2017 Financing [Member]

Basis Of Presentation [Line Items]

Shares issuable upon exercise of warrants (in shares)

1,068,307

Exercise price (in usd per share) | $ / shares

$ 1.67

$ 0.60

Warrant expiration period

2 years 6 months

Underwriter Warrants 2017 [Member] | April 2017 Financing [Member]

Basis Of Presentation [Line Items]

Exercise price (in usd per share) | $ / shares

$ 1.75

Warrant expiration period

5 years

April 2017 Warrants [Member] | April 2017 Financing [Member]

Basis Of Presentation [Line Items]

Exercise price (in usd per share) | $ / shares

$ 1.55

Warrant expiration period

5 years

Placement Agent Warrants [Member] | September 2016 Financing [Member]

Basis Of Presentation [Line Items]

Exercise price (in usd per share) | $ / shares

$ 4.3125

Warrant expiration period

5 years

Private Placement Warrants [Member] | September 2016 Financing [Member]

Basis Of Presentation [Line Items]

Warrant expiration period

5 years 6 months

Warrants Expiring October 2024

Basis Of Presentation [Line Items]

Shares issuable upon exercise of warrants (in shares)

1,000

Exercise price (in usd per share) | $ / shares

$ 387

Warrants Expiring April 2022

Basis Of Presentation [Line Items]

Shares issuable upon exercise of warrants (in shares)

8,000

Exercise price (in usd per share) | $ / shares

$ 52.50

Warrants Expiring March 2024 Tranche 3

Basis Of Presentation [Line Items]

Shares issuable upon exercise of warrants (in shares)

89,000

Exercise price (in usd per share) | $ / shares

$ 12

Warrants Expiring July 2025

Basis Of Presentation [Line Items]

Shares issuable upon exercise of warrants (in shares)

1,000

Exercise price (in usd per share) | $ / shares

$ 492

Warrants Expiring May 2022

Basis Of Presentation [Line Items]

Shares issuable upon exercise of warrants (in shares)

82,000

Exercise price (in usd per share) | $ / shares

$ 46.50

Warrants Expiring May 2023

Basis Of Presentation [Line Items]

Shares issuable upon exercise of warrants (in shares)

80,000

Exercise price (in usd per share) | $ / shares

$ 15

Warrants Expiring March 2023, Tranche 2

Basis Of Presentation [Line Items]

Shares issuable upon exercise of warrants (in shares)

4,000

Exercise price (in usd per share) | $ / shares

$ 21.30

Warrants Expiring January 2023

Basis Of Presentation [Line Items]

Shares issuable upon exercise of warrants (in shares)

11,000

Exercise price (in usd per share) | $ / shares

$ 12.60

Warrants Expiring March 2023

Basis Of Presentation [Line Items]

Shares issuable upon exercise of warrants (in shares)

11,000

Exercise price (in usd per share) | $ / shares

$ 12.60

Warrants Expiring January 2023, Tranche 2

Basis Of Presentation [Line Items]

Shares issuable upon exercise of warrants (in shares)

3,000

Exercise price (in usd per share) | $ / shares

$ 21.30

Warrants Expiring March 2024 Tranche 2

Basis Of Presentation [Line Items]

Shares issuable upon exercise of warrants (in shares)

115,000

Exercise price (in usd per share) | $ / shares

$ 9

Warrants Expiring March 2024

Basis Of Presentation [Line Items]

Shares issuable upon exercise of warrants (in shares)

8,000

Exercise price (in usd per share) | $ / shares

$ 10.14

Warrants Expiring March 2023, Tranche 3

Basis Of Presentation [Line Items]

Shares issuable upon exercise of warrants (in shares)

12,000

Exercise price (in usd per share) | $ / shares

$ 18.90

Private Placement And Placement Agent Warrants [Member] | April 2017 Warrant Amendment [Member]

Basis Of Presentation [Line Items]

Exercise price (in usd per share) | $ / shares

$ 1.55

HC Wainwright [Member] | Common Stock | April 2017 Financing [Member]

Basis Of Presentation [Line Items]

Number of units sold in transaction (in shares)

5,030,000

HC Wainwright [Member] | September 2018 Placement Agent Warrants [Member] | September 2018 Financing [Member]

Basis Of Presentation [Line Items]

Shares issuable upon exercise of warrants (in shares)

230,000

HC Wainwright [Member] | April 2018 Placement Agent Warrants [Member] | April 2018 Financing [Member]

Basis Of Presentation [Line Items]

Shares issuable upon exercise of warrants (in shares)

355,000

HC Wainwright [Member] | Warrants Expiring March 2020, Tranche 2 | September 2017 Financing [Member]

Basis Of Presentation [Line Items]

Shares issuable upon exercise of warrants (in shares)

106,831

HC Wainwright [Member] | Underwriter Warrants 2017 [Member] | April 2017 Financing [Member]

Basis Of Presentation [Line Items]

Shares issuable upon exercise of warrants (in shares)

251,500

Aspire Capital Fund, LLC [Member]

Basis Of Presentation [Line Items]

Issuance of common stock (in shares)

253,165

500,000

Organization and Summary of S_5

Organization and Summary of Significant Accounting Policies - Property and Equipment (Details)	12 Months Ended
	Dec. 31, 2018
Machinery and Equipment | Minimum
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	3 years
Machinery and Equipment | Maximum
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	5 years
Furniture and Fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	10 years
Computer software
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	5 years

Organization and Summary of S_6

Organization and Summary of Significant Accounting Policies - Fair Value Warrant Liabilities Recurring Basis (Details) - Warrant - Fair Value, Measurements, Recurring $ in Thousands	Dec. 31, 2017USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities measured at fair value on a recurring basis	$ 694
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities measured at fair value on a recurring basis	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities measured at fair value on a recurring basis	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities measured at fair value on a recurring basis	$ 694

Organization and Summary of S_7

Organization and Summary of Significant Accounting Policies - Fair Value Valuation Warrant Assumptions (Details) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Dividend yield	0.00%	0.00%
Weighted average fair value (USD per share)	$ 49.88
Minimum
Expected term (in years)	5 years 3 months
Maximum
Expected term (in years)	6 years 29 days
Fair Value, Inputs, Level 3 [Member] | Warrant
Risk-free interest rate, minimum		2.20%
Risk-free interest rate, maximum		2.20%
Dividend yield		0.00%
Weighted average fair value (USD per share)		$ 24
Fair Value, Inputs, Level 3 [Member] | Warrant | Minimum
Volatility		89.41%
Expected term (in years)		5 years 61 days
Fair Value, Inputs, Level 3 [Member] | Warrant | Maximum
Volatility		89.00%
Expected term (in years)		5 years 14 days

Organization and Summary of S_8

Organization and Summary of Significant Accounting Policies - Change in Level 3 Fair Value (Details) - Warrant - Fair Value, Inputs, Level 3 [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2018USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 694
Change in fair value measurement of warrant liability	(222)
Warrant liability reclassified to stockholders' equity	(472)
Ending balance	$ 0

Organization and Summary of S_9

Organization and Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of securities that are antidilutive	475	272
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of securities that are antidilutive	29	12
Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of securities that are antidilutive	437	236
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of securities that are antidilutive	9	24

Organization and Summary of _10

Organization and Summary of Significant Accounting Policies - Segment Information Narrative (Details)	12 Months Ended
	Dec. 31, 2018segment
Accounting Policies [Abstract]
Number of operating segments	1

Organization and Summary of _11

Organization and Summary of Significant Accounting Policies - Geographical Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues by area	$ 0	$ 511
Europe
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues by area	0	364
Canada
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues by area	0	142
Other Countries
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues by area	$ 0	$ 5

Merger - Narrative (Details)

Merger - Narrative (Details) - USD ($)	Jul. 30, 2018	Jul. 31, 2018
Business Acquisition [Line Items]
Expected ownership of surviving company (percent)	15.00%
CVR entitled to receipt of percentage of cash payments exceeding agreement threshold (percent)	90.00%
CVR agreement threshold for sales or out-licensing of assets	$ 500,000
CVR agreement term of cash payout	10 years
Seelos Therapeutics, Inc.
Business Acquisition [Line Items]
Expected ownership of surviving company (percent)		85.00%
CVR agreement right to receive initial proceeds from sales or out-licensing of assets		$ 500,000
CVR agreement right to contingent payment in excess of agreement threshold (percent)		10.00%
Period of time for commercially reasonable efforts to sell or out-license assets		3 years
Reverse stock split ratio		0.03333

Ferring Asset Purchase Agreem_3

Ferring Asset Purchase Agreement and Discontinued Operations - Narrative (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)payment
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Maximum potential proceeds from divestiture	$ 12,700
Proceeds from sale of rights to Vitaros product line	$ 11,500
Number of expected quarterly payments for transition services | payment	2
Payment recognized related to transition services	$ 500
Repayments of debt	6,600
Liabilities assumed by purchaser after closing date	1,100
Aggregate liability under indemnification claims	$ 2,000

Ferring Asset Purchase Agreem_4

Ferring Asset Purchase Agreement and Discontinued Operations - Gain on Sale of Purchased Assets to Ferring (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)
Discontinued Operations and Disposal Groups [Abstract]
Upfront payment received	$ 11,500
Transition services payments	500
Payment received for inventory	709
Total proceeds from sale	12,709
Carrying value of assets sold in sale	(1,578)
Carrying value of assets sold in sale	1,186
Total gain on sale of Purchased Assets	$ 12,317

Ferring Asset Purchase Agreem_5

Ferring Asset Purchase Agreement and Discontinued Operations - Operating Results of Discontinued Operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Product sales		$ 143
Royalty revenue		368
License fee revenue		0
Cost of goods sold		(74)
Cost of Sandoz rights		(10)
Operating expenses		(658)
Other expense		(16)
Gain on sale		12,317
(Loss) income from discontinued operations	$ (24)	$ 12,070
Discontinued Operations, Held-for-sale or Disposed of by Sale [Member] | Product Business Outside The United States [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Product sales	0
Royalty revenue	0
License fee revenue	0
Cost of goods sold	(24)
Cost of Sandoz rights	0
Operating expenses	0
Other expense	0
Gain on sale	0
(Loss) income from discontinued operations	$ (24)

Allergan In-Licensing Agreement

Allergan In-Licensing Agreement - Narrative (Details) - Vitaros [Member] $ in Millions	1 Months Ended
	Apr. 30, 2018clinical_trial	Sep. 30, 2017USD ($)	Sep. 30, 2015USD ($)	Dec. 31, 2018USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of Phase 3 clinical efficacy trials required | clinical_trial	2
Allergan (formerly Warner Chilcott) [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Payments to Allergan, research and development		$ 1.5	$ 1
License fees, potential future milestone payments receivable				$ 25
Allergan (formerly Warner Chilcott) [Member] | Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty rate, potential receivable on future product sales (percent)				20.00%
Allergan (formerly Warner Chilcott) [Member] | Minimum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty rate, potential receivable on future product sales (percent)				10.00%

Other Financial Information - P

Other Financial Information - Property and Equipment (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Property and Equipment
Leasehold improvements	$ 20	$ 20
Machinery and equipment	270	270
Capital lease equipment	76	76
Computer software	130	130
Furniture and fixtures	25	25
Total property and equipment	521	521
Less: accumulated depreciation and amortization	(483)	(442)
Property and equipment, net	38	79
Depreciation expense	$ 40	$ 100

Other Financial Information - A

Other Financial Information - Accrued Expenses (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Payables and Accruals [Abstract]
Professional fees	$ 548	$ 575
Outside research and development services	4	61
Other	92	14
Accrued expenses, net	$ 644	$ 650

Other Financial Information - O

Other Financial Information - Other Long-term Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Deferred rent	$ 4	$ 46
Security deposit	12	12
Other long term liabilities, net	$ 16	$ 58

Stockholders' Equity - Septembe

Stockholders' Equity - September 2018 Financing (Details) $ / shares in Units, $ in Thousands

Sep. 20, 2018USD ($)$ / sharesshares

Apr. 02, 2018USD ($)$ / sharesshares

Sep. 10, 2017USD ($)$ / sharesshares

Apr. 26, 2017USD ($)$ / sharesshares

Jul. 05, 2016shares

Mar. 31, 2018USD ($)

Sep. 30, 2016USD ($)$ / sharesshares

Jul. 31, 2016USD ($)

Jan. 31, 2016shares

Jun. 30, 2017USD ($)

Dec. 31, 2018USD ($)$ / sharesshares

Dec. 31, 2017USD ($)

Sep. 30, 2018shares

Sep. 24, 2018USD ($)

Apr. 30, 2018$ / shares

Apr. 20, 2017USD ($)$ / shares

Mar. 31, 2016

Class of Stock [Line Items]

Shares issuable upon exercise of warrants (in shares) | shares

437,000

Fair value of warrants recorded as equity | $

$ 800

Change in fair value of warrant liability | $

$ (222)

$ 646

Transaction costs | $

$ 690

$ 1,392

September 2018 Financing [Member]

Class of Stock [Line Items]

Net proceeds from sale of common stock and warrants after transaction costs | $

$ 1,100

September 2017 Financing [Member]

Class of Stock [Line Items]

Net proceeds from sale of common stock and warrants after transaction costs | $

$ 3,100

September 2016 Financing [Member]

Class of Stock [Line Items]

Net proceeds from sale of common stock and warrants after transaction costs | $

$ 3,200

Common Stock

Class of Stock [Line Items]

Issuance of common stock (in shares) | shares

8,428

Common Stock | September 2018 Financing [Member]

Class of Stock [Line Items]

Issuance of common stock (in shares) | shares

153,333

Shares issued, price per share (in usd per share)

$ 8.10

Transaction costs | $

$ 200

Common Stock | April 2018 Financing [Member]

Class of Stock [Line Items]

Transaction costs | $

$ 700

Common Stock | September 2017 Financing [Member]

Class of Stock [Line Items]

Issuance of common stock (in shares) | shares

2,136,614

Shares issued, price per share (in usd per share)

$ 1.73

Transaction costs | $

$ 600

Common Stock | April 2017 Financing [Member]

Class of Stock [Line Items]

Transaction costs | $

$ 1,100

Common Stock | September 2016 Financing [Member]

Class of Stock [Line Items]

Issuance of common stock (in shares) | shares

1,082,402

Shares issued, price per share (in usd per share)

$ 3.45

Transaction costs | $

$ 400

September 2018 Placement Agent Warrants [Member] | September 2018 Financing [Member]

Class of Stock [Line Items]

Warrant vesting period

6 months

Warrant exercise price (in usd per share)

$ 0.3375

Warrant expiration period

5 years

September 2018 Placement Agent Warrants [Member] | September 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Option Volatility [Member]

Class of Stock [Line Items]

Warrants, measurement input

1.073

September 2018 Placement Agent Warrants [Member] | September 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Risk Free Interest Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0.0297

September 2018 Placement Agent Warrants [Member] | September 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Expected Dividend Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0

September 2018 Warrants, Tranche 2 [Member] | September 2018 Financing [Member]

Class of Stock [Line Items]

Shares issuable upon exercise of warrants (in shares) | shares

2,677,160

Warrant vesting period

6 months

Warrant exercise price (in usd per share)

$ 0.40

September 2018 Warrants, Tranche 1 [Member] | September 2018 Financing [Member]

Class of Stock [Line Items]

Shares issuable upon exercise of warrants (in shares) | shares

3,450,000

Warrant vesting period

6 months

Warrant exercise price (in usd per share)

$ 0.30

September 2018 Warrants [Member] | September 2018 Financing [Member]

Class of Stock [Line Items]

Warrant expiration period

5 years

September 2018 Warrants [Member] | September 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Option Volatility [Member]

Class of Stock [Line Items]

Warrants, measurement input

1.073

September 2018 Warrants [Member] | September 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Risk Free Interest Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0.0297

September 2018 Warrants [Member] | September 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Expected Dividend Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0

April 2018 Placement Agent Warrants [Member] | April 2018 Financing [Member]

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 0.625

Warrant expiration period

5 years

April 2018 Placement Agent Warrants [Member] | April 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Option Volatility [Member]

Class of Stock [Line Items]

Warrants, measurement input

1.05

April 2018 Placement Agent Warrants [Member] | April 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Risk Free Interest Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0.0255

April 2018 Placement Agent Warrants [Member] | April 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Expected Dividend Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0

April 2018 Warrants [Member] | April 2018 Financing [Member]

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 0.50

Warrant expiration period

5 years

April 2018 Warrants [Member] | April 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Option Volatility [Member]

Class of Stock [Line Items]

Warrants, measurement input

1.040

April 2018 Warrants [Member] | April 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Risk Free Interest Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0.0255

April 2018 Warrants [Member] | April 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Expected Dividend Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0

September 2017 Financing Warrants [Member] | September 2017 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Option Volatility [Member]

Class of Stock [Line Items]

Warrants, measurement input

1.104

September 2017 Financing Warrants [Member] | September 2017 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Risk Free Interest Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0.0138

September 2017 Financing Warrants [Member] | September 2017 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Expected Dividend Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0

Warrants Expiring March 2020, Tranche 1 [Member] | September 2017 Financing [Member]

Class of Stock [Line Items]

Shares issuable upon exercise of warrants (in shares) | shares

1,068,307

Warrant exercise price (in usd per share)

$ 1.67

$ 0.60

Warrant expiration period

2 years 6 months

Warrants Expiring March 2020, Tranche 2

Class of Stock [Line Items]

Shares issuable upon exercise of warrants (in shares) | shares

13,000

Warrant exercise price (in usd per share)

$ 18

Warrants Expiring March 2020, Tranche 2 | September 2017 Financing [Member]

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 2.16

$ 0.60

Warrant expiration period

2 years 6 months

Underwriter Warrants 2017 [Member] | April 2017 Financing [Member]

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 1.75

Warrant expiration period

5 years

Underwriter Warrants 2017 [Member] | April 2017 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Option Volatility [Member]

Class of Stock [Line Items]

Warrants, measurement input

0.887

April 2017 Warrants [Member] | April 2017 Financing [Member]

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 1.55

Warrant expiration period

5 years

April 2017 Warrants [Member] | April 2017 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Option Volatility [Member]

Class of Stock [Line Items]

Warrants, measurement input

0.883

Placement Agent Warrants [Member] | September 2016 Financing [Member]

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 4.3125

Warrant expiration period

5 years

Private Placement Warrants [Member] | September 2016 Financing [Member]

Class of Stock [Line Items]

Warrant expiration period

5 years 6 months

February 2015 And January 2016 Warrants [Member]

Class of Stock [Line Items]

Fair value of warrants recorded as equity | $

$ 500

Change in fair value of warrant liability | $

$ 100

Common Stock | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Option Volatility [Member]

Class of Stock [Line Items]

Warrants, measurement input

1.019

0.994

Common Stock | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Risk Free Interest Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0.016

0.014

Common Stock | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Expected Dividend Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0

0

Private Placement And Placement Agent Warrants [Member] | April 2017 Warrant Amendment [Member]

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 1.55

Change in fair value of warrant liability | $

$ 200

Warrants Expiring May 2022

Class of Stock [Line Items]

Shares issuable upon exercise of warrants (in shares) | shares

82,000

Warrant exercise price (in usd per share)

$ 46.50

Warrants Expiring March 2023, Tranche 2

Class of Stock [Line Items]

Shares issuable upon exercise of warrants (in shares) | shares

4,000

Warrant exercise price (in usd per share)

$ 21.30

Warrants Expiring January 2023

Class of Stock [Line Items]

Shares issuable upon exercise of warrants (in shares) | shares

11,000

Warrant exercise price (in usd per share)

$ 12.60

Warrants Expiring March 2023, Tranche 3

Class of Stock [Line Items]

Shares issuable upon exercise of warrants (in shares) | shares

12,000

Warrant exercise price (in usd per share)

$ 18.90

Warrants Expiring March 2024 Tranche 2

Class of Stock [Line Items]

Shares issuable upon exercise of warrants (in shares) | shares

115,000

Warrant exercise price (in usd per share)

$ 9

Warrants Expiring October 2024

Class of Stock [Line Items]

Shares issuable upon exercise of warrants (in shares) | shares

1,000

Warrant exercise price (in usd per share)

$ 387

Warrants Expiring April 2022

Class of Stock [Line Items]

Shares issuable upon exercise of warrants (in shares) | shares

8,000

Warrant exercise price (in usd per share)

$ 52.50

Warrants Expiring March 2024 Tranche 3

Class of Stock [Line Items]

Shares issuable upon exercise of warrants (in shares) | shares

89,000

Warrant exercise price (in usd per share)

$ 12

Warrants Expiring July 2025

Class of Stock [Line Items]

Shares issuable upon exercise of warrants (in shares) | shares

1,000

Warrant exercise price (in usd per share)

$ 492

Warrants Expiring May 2023

Class of Stock [Line Items]

Shares issuable upon exercise of warrants (in shares) | shares

80,000

Warrant exercise price (in usd per share)

$ 15

Warrants Expiring March 2024

Class of Stock [Line Items]

Shares issuable upon exercise of warrants (in shares) | shares

8,000

Warrant exercise price (in usd per share)

$ 10.14

Warrants Expiring January 2023, Tranche 2

Class of Stock [Line Items]

Shares issuable upon exercise of warrants (in shares) | shares

3,000

Warrant exercise price (in usd per share)

$ 21.30

Warrants Expiring March 2023

Class of Stock [Line Items]

Shares issuable upon exercise of warrants (in shares) | shares

11,000

Warrant exercise price (in usd per share)

$ 12.60

Warrants Cancelled [Member]

Class of Stock [Line Items]

Fair value of warrants recorded as equity | $

$ 600

September 2018 Warrants And Placement Agent Warrants [Member]

Class of Stock [Line Items]

Fair value of warrants recorded as equity | $

$ 900

April 2018 Warrants And Placement Agent Warrants [Member]

Class of Stock [Line Items]

Fair value of warrants recorded as equity | $

$ 1,200

April 2017 Financing Warrants [Member] | April 2017 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Risk Free Interest Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0.018

April 2017 Financing Warrants [Member] | April 2017 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Expected Dividend Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0

Aspire Capital Fund, LLC [Member]

Class of Stock [Line Items]

Issuance of common stock (in shares) | shares

253,165

500,000

Transaction costs | $

$ 100

HC Wainwright [Member] | September 2018 Placement Agent Warrants [Member] | September 2018 Financing [Member]

Class of Stock [Line Items]

Shares issuable upon exercise of warrants (in shares) | shares

230,000

HC Wainwright [Member] | April 2018 Placement Agent Warrants [Member] | April 2018 Financing [Member]

Class of Stock [Line Items]

Shares issuable upon exercise of warrants (in shares) | shares

355,000

HC Wainwright [Member] | Warrants Expiring March 2020, Tranche 2 | September 2017 Financing [Member]

Class of Stock [Line Items]

Shares issuable upon exercise of warrants (in shares) | shares

106,831

HC Wainwright [Member] | Underwriter Warrants 2017 [Member] | April 2017 Financing [Member]

Class of Stock [Line Items]

Shares issuable upon exercise of warrants (in shares) | shares

251,500

Stockholders' Equity - June and

Stockholders' Equity - June and March 2018 Warrant Amendments (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2017	Sep. 24, 2018	Sep. 20, 2018	Apr. 02, 2018	Apr. 20, 2017
Class of Stock [Line Items]
Amendment of equity classified warrants		$ 293	$ 0
Fair value of warrants recorded as equity							$ 800
Change in fair value of warrant liability		$ (222)	$ 646
February 2015 And January 2016 Warrants [Member]
Class of Stock [Line Items]
Fair value of warrants recorded as equity	$ 500
Change in fair value of warrant liability	$ 100
Warrants Expiring May 2022
Class of Stock [Line Items]
Warrant exercise price (in usd per share)		$ 46.50
Warrants Expiring March 2023, Tranche 2
Class of Stock [Line Items]
Warrant exercise price (in usd per share)		21.30
Warrants Expiring January 2023
Class of Stock [Line Items]
Warrant exercise price (in usd per share)		12.60
Warrants Expiring March 2024
Class of Stock [Line Items]
Warrant exercise price (in usd per share)		10.14
Warrants Expiring January 2023, Tranche 2
Class of Stock [Line Items]
Warrant exercise price (in usd per share)		21.30
Warrants Expiring March 2023
Class of Stock [Line Items]
Warrant exercise price (in usd per share)		12.60
Warrants Expiring May 2023
Class of Stock [Line Items]
Warrant exercise price (in usd per share)		15
Warrants Expiring July 2025
Class of Stock [Line Items]
Warrant exercise price (in usd per share)		492
Warrants Expiring March 2024 Tranche 3
Class of Stock [Line Items]
Warrant exercise price (in usd per share)		12
Warrants Expiring April 2022
Class of Stock [Line Items]
Warrant exercise price (in usd per share)		52.50
Warrants Expiring October 2024
Class of Stock [Line Items]
Warrant exercise price (in usd per share)		387
Warrants Expiring March 2024 Tranche 2
Class of Stock [Line Items]
Warrant exercise price (in usd per share)		9
Warrants Expiring March 2020, Tranche 2
Class of Stock [Line Items]
Warrant exercise price (in usd per share)		18
Warrants Expiring March 2023, Tranche 3
Class of Stock [Line Items]
Warrant exercise price (in usd per share)		$ 18.90
Warrants Cancelled [Member]
Class of Stock [Line Items]
Fair value of warrants recorded as equity				$ 600
September 2018 Warrants And Placement Agent Warrants [Member]
Class of Stock [Line Items]
Fair value of warrants recorded as equity					$ 900
April 2018 Warrants And Placement Agent Warrants [Member]
Class of Stock [Line Items]
Fair value of warrants recorded as equity						$ 1,200

Stockholders' Equity - April 20

Stockholders' Equity - April 2018 Financing & Warrant Amendment (Details) $ / shares in Units, $ in Thousands

Sep. 20, 2018USD ($)$ / sharesshares

Apr. 02, 2018USD ($)$ / sharesshares

Sep. 10, 2017USD ($)$ / sharesshares

Apr. 26, 2017USD ($)$ / sharesshares

Sep. 30, 2016USD ($)$ / shares

Jul. 31, 2016USD ($)

Dec. 31, 2018USD ($)$ / sharesshares

Dec. 31, 2017USD ($)

Sep. 24, 2018USD ($)

Apr. 30, 2018$ / shares

Mar. 31, 2018USD ($)

Apr. 20, 2017USD ($)$ / shares

Mar. 31, 2016

Jan. 31, 2016

Class of Stock [Line Items]

Shares issuable upon exercise of warrants (in shares) | shares

437,000

Fair value of warrants recorded as equity | $

$ 800

Transaction costs | $

$ 690

$ 1,392

Common Stock | September 2018 Financing [Member]

Class of Stock [Line Items]

Transaction costs | $

$ 200

Common Stock | April 2018 Financing [Member]

Class of Stock [Line Items]

Net proceeds from financing transaction | $

$ 2,900

Number of units sold in transaction (in shares) | shares

7,100,000

Transaction costs | $

$ 700

Common Stock | September 2017 Financing [Member]

Class of Stock [Line Items]

Transaction costs | $

$ 600

Common Stock | April 2017 Financing [Member]

Class of Stock [Line Items]

Net proceeds from financing transaction | $

$ 5,900

Transaction costs | $

$ 1,100

Common Stock | September 2016 Financing [Member]

Class of Stock [Line Items]

Transaction costs | $

$ 400

September 2018 Warrants [Member] | September 2018 Financing [Member]

Class of Stock [Line Items]

Warrant expiration period

5 years

September 2018 Warrants [Member] | September 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Option Volatility [Member]

Class of Stock [Line Items]

Warrants, measurement input

1.073

September 2018 Warrants [Member] | September 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Risk Free Interest Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0.0297

September 2018 Warrants [Member] | September 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Expected Dividend Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0

September 2018 Placement Agent Warrants [Member] | September 2018 Financing [Member]

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 0.3375

Warrant expiration period

5 years

September 2018 Placement Agent Warrants [Member] | September 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Option Volatility [Member]

Class of Stock [Line Items]

Warrants, measurement input

1.073

September 2018 Placement Agent Warrants [Member] | September 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Risk Free Interest Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0.0297

September 2018 Placement Agent Warrants [Member] | September 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Expected Dividend Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0

April 2018 Placement Agent Warrants [Member] | April 2018 Financing [Member]

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 0.625

Warrant expiration period

5 years

April 2018 Placement Agent Warrants [Member] | April 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Option Volatility [Member]

Class of Stock [Line Items]

Warrants, measurement input

1.05

April 2018 Placement Agent Warrants [Member] | April 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Risk Free Interest Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0.0255

April 2018 Placement Agent Warrants [Member] | April 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Expected Dividend Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0

April 2018 Warrants [Member] | April 2018 Financing [Member]

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 0.50

Warrant expiration period

5 years

April 2018 Warrants [Member] | April 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Option Volatility [Member]

Class of Stock [Line Items]

Warrants, measurement input

1.040

April 2018 Warrants [Member] | April 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Risk Free Interest Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0.0255

April 2018 Warrants [Member] | April 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Expected Dividend Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0

September 2017 Financing Warrants [Member] | September 2017 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Option Volatility [Member]

Class of Stock [Line Items]

Warrants, measurement input

1.104

September 2017 Financing Warrants [Member] | September 2017 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Risk Free Interest Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0.0138

September 2017 Financing Warrants [Member] | September 2017 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Expected Dividend Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0

Warrants Expiring March 2020, Tranche 2

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 18

Shares issuable upon exercise of warrants (in shares) | shares

13,000

Warrants Expiring March 2020, Tranche 2 | September 2017 Financing [Member]

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 2.16

$ 0.60

Warrant expiration period

2 years 6 months

Warrants Expiring March 2020, Tranche 1 [Member] | September 2017 Financing [Member]

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 1.67

$ 0.60

Warrant expiration period

2 years 6 months

Shares issuable upon exercise of warrants (in shares) | shares

1,068,307

Underwriter Warrants 2017 [Member] | April 2017 Financing [Member]

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 1.75

Warrant expiration period

5 years

Underwriter Warrants 2017 [Member] | April 2017 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Option Volatility [Member]

Class of Stock [Line Items]

Warrants, measurement input

0.887

April 2017 Warrants [Member] | April 2017 Financing [Member]

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 1.55

Warrant expiration period

5 years

April 2017 Warrants [Member] | April 2017 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Option Volatility [Member]

Class of Stock [Line Items]

Warrants, measurement input

0.883

Private Placement Warrants [Member] | September 2016 Financing [Member]

Class of Stock [Line Items]

Warrant expiration period

5 years 6 months

Placement Agent Warrants [Member] | September 2016 Financing [Member]

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 4.3125

Warrant expiration period

5 years

Common Stock | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Option Volatility [Member]

Class of Stock [Line Items]

Warrants, measurement input

0.994

1.019

Common Stock | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Risk Free Interest Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0.014

0.016

Common Stock | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Expected Dividend Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0

0

Warrants Expiring May 2022

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 46.50

Shares issuable upon exercise of warrants (in shares) | shares

82,000

Warrants Expiring March 2023, Tranche 2

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 21.30

Shares issuable upon exercise of warrants (in shares) | shares

4,000

Warrants Expiring January 2023

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 12.60

Shares issuable upon exercise of warrants (in shares) | shares

11,000

Warrants Expiring March 2023, Tranche 3

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 18.90

Shares issuable upon exercise of warrants (in shares) | shares

12,000

Warrants Expiring March 2024 Tranche 2

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 9

Shares issuable upon exercise of warrants (in shares) | shares

115,000

Warrants Expiring October 2024

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 387

Shares issuable upon exercise of warrants (in shares) | shares

1,000

Warrants Expiring April 2022

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 52.50

Shares issuable upon exercise of warrants (in shares) | shares

8,000

Warrants Expiring March 2024 Tranche 3

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 12

Shares issuable upon exercise of warrants (in shares) | shares

89,000

Warrants Expiring July 2025

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 492

Shares issuable upon exercise of warrants (in shares) | shares

1,000

Warrants Expiring May 2023

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 15

Shares issuable upon exercise of warrants (in shares) | shares

80,000

Warrants Expiring March 2023

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 12.60

Shares issuable upon exercise of warrants (in shares) | shares

11,000

Warrants Expiring January 2023, Tranche 2

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 21.30

Shares issuable upon exercise of warrants (in shares) | shares

3,000

Warrants Expiring March 2024

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 10.14

Shares issuable upon exercise of warrants (in shares) | shares

8,000

Warrants Cancelled [Member]

Class of Stock [Line Items]

Fair value of warrants recorded as equity | $

$ 600

September 2018 Warrants, Tranche 1 [Member] | September 2018 Financing [Member]

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 0.30

Shares issuable upon exercise of warrants (in shares) | shares

3,450,000

September 2018 Warrants, Tranche 2 [Member] | September 2018 Financing [Member]

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 0.40

Shares issuable upon exercise of warrants (in shares) | shares

2,677,160

September 2018 Warrants And Placement Agent Warrants [Member]

Class of Stock [Line Items]

Fair value of warrants recorded as equity | $

$ 900

February 2015 And January 2016 Warrants [Member]

Class of Stock [Line Items]

Fair value of warrants recorded as equity | $

$ 500

April 2018 Warrants And Placement Agent Warrants [Member]

Class of Stock [Line Items]

Fair value of warrants recorded as equity | $

$ 1,200

April 2017 Financing Warrants [Member] | April 2017 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Risk Free Interest Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0.018

April 2017 Financing Warrants [Member] | April 2017 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Expected Dividend Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0

Private Placement And Placement Agent Warrants [Member] | April 2017 Warrant Amendment [Member]

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 1.55

HC Wainwright [Member] | Common Stock | April 2017 Financing [Member]

Class of Stock [Line Items]

Number of units sold in transaction (in shares) | shares

5,030,000

HC Wainwright [Member] | September 2018 Placement Agent Warrants [Member] | September 2018 Financing [Member]

Class of Stock [Line Items]

Shares issuable upon exercise of warrants (in shares) | shares

230,000

HC Wainwright [Member] | April 2018 Placement Agent Warrants [Member] | April 2018 Financing [Member]

Class of Stock [Line Items]

Shares issuable upon exercise of warrants (in shares) | shares

355,000

HC Wainwright [Member] | Warrants Expiring March 2020, Tranche 2 | September 2017 Financing [Member]

Class of Stock [Line Items]

Shares issuable upon exercise of warrants (in shares) | shares

106,831

HC Wainwright [Member] | Underwriter Warrants 2017 [Member] | April 2017 Financing [Member]

Class of Stock [Line Items]

Shares issuable upon exercise of warrants (in shares) | shares

251,500

Aspire Capital Fund, LLC [Member]

Class of Stock [Line Items]

Transaction costs | $

$ 100

Stockholders' Equity - Septem_2

Stockholders' Equity - September 2017 Financing (Details) $ / shares in Units, $ in Thousands

Sep. 20, 2018USD ($)$ / sharesshares

Apr. 02, 2018USD ($)$ / shares

Sep. 10, 2017USD ($)$ / sharesshares

Apr. 26, 2017USD ($)$ / shares

Jul. 05, 2016shares

Sep. 30, 2016USD ($)$ / sharesshares

Jul. 31, 2016USD ($)

Mar. 31, 2016USD ($)

Jan. 31, 2016USD ($)shares

Dec. 31, 2018USD ($)$ / shares

Dec. 31, 2017USD ($)

Sep. 30, 2018shares

Apr. 30, 2018$ / shares

Apr. 20, 2017$ / shares

Class of Stock [Line Items]

Aggregate gross proceeds from sale of common stock and warrants | $

$ 7,800

$ 2,200

Transaction costs | $

$ 690

$ 1,392

Amendment of equity classified warrants | $

$ 293

$ 0

September 2018 Financing [Member]

Class of Stock [Line Items]

Net proceeds from sale of common stock and warrants after transaction costs | $

$ 1,100

September 2017 Financing [Member]

Class of Stock [Line Items]

Net proceeds from sale of common stock and warrants after transaction costs | $

$ 3,100

September 2016 Financing [Member]

Class of Stock [Line Items]

Net proceeds from sale of common stock and warrants after transaction costs | $

$ 3,200

Aggregate gross proceeds from sale of common stock and warrants | $

$ 3,700

Common Stock

Class of Stock [Line Items]

Issuance of common stock (in shares) | shares

8,428

Common Stock | September 2018 Financing [Member]

Class of Stock [Line Items]

Issuance of common stock (in shares) | shares

153,333

Shares issued, price per share (in usd per share)

$ 8.10

Transaction costs | $

$ 200

Common Stock | April 2018 Financing [Member]

Class of Stock [Line Items]

Transaction costs | $

$ 700

Common Stock | September 2017 Financing [Member]

Class of Stock [Line Items]

Issuance of common stock (in shares) | shares

2,136,614

Shares issued, price per share (in usd per share)

$ 1.73

Aggregate gross proceeds from sale of common stock and warrants | $

$ 2,800

Transaction costs | $

$ 600

Common Stock | April 2017 Financing [Member]

Class of Stock [Line Items]

Transaction costs | $

$ 1,100

Common Stock | September 2016 Financing [Member]

Class of Stock [Line Items]

Issuance of common stock (in shares) | shares

1,082,402

Shares issued, price per share (in usd per share)

$ 3.45

Transaction costs | $

$ 400

September 2018 Warrants [Member] | September 2018 Financing [Member]

Class of Stock [Line Items]

Warrant expiration period

5 years

September 2018 Warrants [Member] | September 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Expected Dividend Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0

September 2018 Warrants [Member] | September 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Option Volatility [Member]

Class of Stock [Line Items]

Warrants, measurement input

1.073

September 2018 Warrants [Member] | September 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Risk Free Interest Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0.0297

September 2018 Placement Agent Warrants [Member] | September 2018 Financing [Member]

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 0.3375

Warrant expiration period

5 years

September 2018 Placement Agent Warrants [Member] | September 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Expected Dividend Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0

September 2018 Placement Agent Warrants [Member] | September 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Option Volatility [Member]

Class of Stock [Line Items]

Warrants, measurement input

1.073

September 2018 Placement Agent Warrants [Member] | September 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Risk Free Interest Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0.0297

April 2018 Warrants [Member] | April 2018 Financing [Member]

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 0.50

Warrant expiration period

5 years

April 2018 Warrants [Member] | April 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Expected Dividend Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0

April 2018 Warrants [Member] | April 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Option Volatility [Member]

Class of Stock [Line Items]

Warrants, measurement input

1.040

April 2018 Warrants [Member] | April 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Risk Free Interest Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0.0255

April 2018 Placement Agent Warrants [Member] | April 2018 Financing [Member]

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 0.625

Warrant expiration period

5 years

April 2018 Placement Agent Warrants [Member] | April 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Expected Dividend Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0

April 2018 Placement Agent Warrants [Member] | April 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Option Volatility [Member]

Class of Stock [Line Items]

Warrants, measurement input

1.05

April 2018 Placement Agent Warrants [Member] | April 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Risk Free Interest Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0.0255

September 2017 Financing Warrants [Member] | September 2017 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Expected Dividend Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0

September 2017 Financing Warrants [Member] | September 2017 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Option Volatility [Member]

Class of Stock [Line Items]

Warrants, measurement input

1.104

September 2017 Financing Warrants [Member] | September 2017 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Risk Free Interest Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0.0138

September 2017 Financing Warrants [Member] | Warrants Not Settleable in Cash [Member] | September 2017 Financing [Member]

Class of Stock [Line Items]

Aggregate gross proceeds from sale of common stock and warrants | $

$ 900

Warrants Expiring March 2020, Tranche 1 [Member] | September 2017 Financing [Member]

Class of Stock [Line Items]

Date from which warrants are exercisable

Sep. 13, 2017

Warrant exercise price (in usd per share)

$ 1.67

$ 0.60

Warrant expiration period

2 years 6 months

Warrants Expiring March 2020, Tranche 2

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 18

Warrants Expiring March 2020, Tranche 2 | September 2017 Financing [Member]

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 2.16

$ 0.60

Warrant expiration period

2 years 6 months

April 2017 Warrants [Member] | April 2017 Financing [Member]

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 1.55

Warrant expiration period

5 years

April 2017 Warrants [Member] | April 2017 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Option Volatility [Member]

Class of Stock [Line Items]

Warrants, measurement input

0.883

Underwriter Warrants 2017 [Member] | April 2017 Financing [Member]

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 1.75

Warrant expiration period

5 years

Underwriter Warrants 2017 [Member] | April 2017 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Option Volatility [Member]

Class of Stock [Line Items]

Warrants, measurement input

0.887

Private Placement Warrants [Member] | September 2016 Financing [Member]

Class of Stock [Line Items]

Warrant expiration period

5 years 6 months

Placement Agent Warrants [Member] | September 2016 Financing [Member]

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 4.3125

Warrant expiration period

5 years

Common Stock | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Expected Dividend Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0

0

Common Stock | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Option Volatility [Member]

Class of Stock [Line Items]

Warrants, measurement input

0.994

1.019

Common Stock | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Risk Free Interest Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0.014

0.016

Warrants Expiring July 2025

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

492

Warrants Expiring May 2023

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

15

Warrants Expiring March 2023

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

12.60

Warrants Expiring January 2023, Tranche 2

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

21.30

Warrants Expiring May 2022

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

46.50

Warrants Expiring March 2024

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

10.14

Warrants Expiring March 2023, Tranche 2

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

21.30

Warrants Expiring January 2023

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

12.60

Warrants Expiring April 2022

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

52.50

Warrants Expiring March 2024 Tranche 3

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

12

Warrants Expiring March 2023, Tranche 3

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

18.90

Warrants Expiring October 2024

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

387

Warrants Expiring March 2024 Tranche 2

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 9

September 2018 Warrants, Tranche 1 [Member] | September 2018 Financing [Member]

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 0.30

September 2018 Warrants, Tranche 2 [Member] | September 2018 Financing [Member]

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 0.40

April 2017 Financing Warrants [Member] | April 2017 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Expected Dividend Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0

April 2017 Financing Warrants [Member] | April 2017 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Risk Free Interest Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0.018

Private Placement And Placement Agent Warrants [Member] | April 2017 Warrant Amendment [Member]

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 1.55

Aspire Capital Fund, LLC [Member]

Class of Stock [Line Items]

Issuance of common stock (in shares) | shares

253,165

500,000

Transaction costs | $

$ 100

Stockholders' Equity - April _2

Stockholders' Equity - April 2017 Financing & Warrant Amendment (Details) $ / shares in Units, $ in Thousands

Sep. 20, 2018USD ($)$ / shares

Apr. 02, 2018USD ($)$ / sharesshares

Sep. 10, 2017USD ($)$ / shares

Apr. 26, 2017USD ($)$ / sharesshares

Sep. 30, 2016USD ($)$ / shares

Jul. 31, 2016USD ($)

Dec. 31, 2018USD ($)$ / shares

Dec. 31, 2017USD ($)

Sep. 24, 2018USD ($)

Apr. 30, 2018$ / shares

Mar. 31, 2018USD ($)

Apr. 20, 2017USD ($)$ / shares

Mar. 31, 2016

Jan. 31, 2016

Class of Stock [Line Items]

Fair value of warrants recorded as equity | $

$ 800

Transaction costs | $

$ 690

$ 1,392

Common Stock | September 2018 Financing [Member]

Class of Stock [Line Items]

Transaction costs | $

$ 200

Common Stock | April 2018 Financing [Member]

Class of Stock [Line Items]

Net proceeds from financing transaction | $

$ 2,900

Number of units sold in transaction (in shares) | shares

7,100,000

Transaction costs | $

$ 700

Common Stock | September 2017 Financing [Member]

Class of Stock [Line Items]

Transaction costs | $

$ 600

Common Stock | April 2017 Financing [Member]

Class of Stock [Line Items]

Net proceeds from financing transaction | $

$ 5,900

Transaction costs | $

$ 1,100

Common Stock | September 2016 Financing [Member]

Class of Stock [Line Items]

Transaction costs | $

$ 400

September 2018 Warrants [Member] | September 2018 Financing [Member]

Class of Stock [Line Items]

Warrant expiration period

5 years

September 2018 Warrants [Member] | September 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Expected Dividend Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0

September 2018 Warrants [Member] | September 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Option Volatility [Member]

Class of Stock [Line Items]

Warrants, measurement input

1.073

September 2018 Warrants [Member] | September 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Risk Free Interest Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0.0297

September 2018 Placement Agent Warrants [Member] | September 2018 Financing [Member]

Class of Stock [Line Items]

Warrant expiration period

5 years

Warrant exercise price (in usd per share)

$ 0.3375

September 2018 Placement Agent Warrants [Member] | September 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Expected Dividend Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0

September 2018 Placement Agent Warrants [Member] | September 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Option Volatility [Member]

Class of Stock [Line Items]

Warrants, measurement input

1.073

September 2018 Placement Agent Warrants [Member] | September 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Risk Free Interest Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0.0297

April 2018 Placement Agent Warrants [Member] | April 2018 Financing [Member]

Class of Stock [Line Items]

Warrant expiration period

5 years

Warrant exercise price (in usd per share)

$ 0.625

April 2018 Placement Agent Warrants [Member] | April 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Expected Dividend Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0

April 2018 Placement Agent Warrants [Member] | April 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Option Volatility [Member]

Class of Stock [Line Items]

Warrants, measurement input

1.05

April 2018 Placement Agent Warrants [Member] | April 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Risk Free Interest Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0.0255

April 2018 Warrants [Member] | April 2018 Financing [Member]

Class of Stock [Line Items]

Warrant expiration period

5 years

Warrant exercise price (in usd per share)

$ 0.50

April 2018 Warrants [Member] | April 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Expected Dividend Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0

April 2018 Warrants [Member] | April 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Option Volatility [Member]

Class of Stock [Line Items]

Warrants, measurement input

1.040

April 2018 Warrants [Member] | April 2018 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Risk Free Interest Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0.0255

September 2017 Financing Warrants [Member] | September 2017 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Expected Dividend Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0

September 2017 Financing Warrants [Member] | September 2017 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Option Volatility [Member]

Class of Stock [Line Items]

Warrants, measurement input

1.104

September 2017 Financing Warrants [Member] | September 2017 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Risk Free Interest Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0.0138

Warrants Expiring March 2020, Tranche 2

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 18

Warrants Expiring March 2020, Tranche 2 | September 2017 Financing [Member]

Class of Stock [Line Items]

Warrant expiration period

2 years 6 months

Warrant exercise price (in usd per share)

$ 2.16

$ 0.60

Warrants Expiring March 2020, Tranche 1 [Member] | September 2017 Financing [Member]

Class of Stock [Line Items]

Warrant expiration period

2 years 6 months

Warrant exercise price (in usd per share)

$ 1.67

$ 0.60

Underwriter Warrants 2017 [Member] | April 2017 Financing [Member]

Class of Stock [Line Items]

Warrant expiration period

5 years

Warrant exercise price (in usd per share)

$ 1.75

Underwriter Warrants 2017 [Member] | April 2017 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Option Volatility [Member]

Class of Stock [Line Items]

Warrants, measurement input

0.887

April 2017 Warrants [Member] | April 2017 Financing [Member]

Class of Stock [Line Items]

Warrant expiration period

5 years

Warrant exercise price (in usd per share)

$ 1.55

April 2017 Warrants [Member] | April 2017 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Option Volatility [Member]

Class of Stock [Line Items]

Warrants, measurement input

0.883

Private Placement Warrants [Member] | September 2016 Financing [Member]

Class of Stock [Line Items]

Warrant expiration period

5 years 6 months

Placement Agent Warrants [Member] | September 2016 Financing [Member]

Class of Stock [Line Items]

Warrant expiration period

5 years

Warrant exercise price (in usd per share)

$ 4.3125

Common Stock | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Expected Dividend Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0

0

Common Stock | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Option Volatility [Member]

Class of Stock [Line Items]

Warrants, measurement input

0.994

1.019

Common Stock | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Risk Free Interest Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0.014

0.016

Warrants Expiring May 2022

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

46.50

Warrants Expiring March 2023, Tranche 2

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

21.30

Warrants Expiring January 2023

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

12.60

Warrants Expiring March 2023, Tranche 3

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

18.90

Warrants Expiring March 2024 Tranche 2

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

9

Warrants Expiring October 2024

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

387

Warrants Expiring April 2022

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

52.50

Warrants Expiring March 2024 Tranche 3

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

12

Warrants Expiring July 2025

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

492

Warrants Expiring May 2023

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

15

Warrants Expiring March 2023

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

12.60

Warrants Expiring January 2023, Tranche 2

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

21.30

Warrants Expiring March 2024

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 10.14

Warrants Cancelled [Member]

Class of Stock [Line Items]

Fair value of warrants recorded as equity | $

$ 600

September 2018 Warrants And Placement Agent Warrants [Member]

Class of Stock [Line Items]

Fair value of warrants recorded as equity | $

$ 900

September 2018 Warrants, Tranche 2 [Member] | September 2018 Financing [Member]

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 0.40

September 2018 Warrants, Tranche 1 [Member] | September 2018 Financing [Member]

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 0.30

February 2015 And January 2016 Warrants [Member]

Class of Stock [Line Items]

Fair value of warrants recorded as equity | $

$ 500

April 2018 Warrants And Placement Agent Warrants [Member]

Class of Stock [Line Items]

Fair value of warrants recorded as equity | $

$ 1,200

April 2017 Financing Warrants [Member] | April 2017 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Expected Dividend Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0

April 2017 Financing Warrants [Member] | April 2017 Financing [Member] | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Risk Free Interest Rate [Member]

Class of Stock [Line Items]

Warrants, measurement input

0.018

April 2017 Financing Warrants [Member] | Warrants Not Settleable in Cash [Member]

Class of Stock [Line Items]

Fair value of warrants recorded as equity | $

$ 2,900

Private Placement And Placement Agent Warrants [Member] | April 2017 Warrant Amendment [Member]

Class of Stock [Line Items]

Warrant exercise price (in usd per share)

$ 1.55

HC Wainwright [Member] | Common Stock | April 2017 Financing [Member]

Class of Stock [Line Items]

Number of units sold in transaction (in shares) | shares

5,030,000

Aspire Capital Fund, LLC [Member]

Class of Stock [Line Items]

Transaction costs | $

$ 100

Stockholders' Equity - Septem_3

Stockholders' Equity - September 2016 Financing (Details) - USD ($) $ / shares in Units, $ in Thousands

Sep. 20, 2018

Apr. 02, 2018

Sep. 10, 2017

Apr. 26, 2017

Mar. 31, 2018

Sep. 30, 2016

Mar. 31, 2016

Jan. 31, 2016

Jun. 30, 2017

Sep. 30, 2016

Dec. 31, 2018

Dec. 31, 2017

Sep. 24, 2018

Apr. 30, 2018

Apr. 20, 2017

Stockholders Equity Note [Line Items]

Aggregate gross proceeds from sale of common stock and warrants

$ 7,800

$ 2,200

Shares issuable upon exercise of warrants (in shares)

437,000

Other financing costs

$ 400

Transaction costs

$ 690

$ 1,392

Fair value of warrants recorded as equity

$ 800

Change in fair value of warrant liability

$ (222)

$ 646

September 2018 Financing [Member]

Stockholders Equity Note [Line Items]

Net proceeds from sale of common stock and warrants after transaction costs

$ 1,100

September 2017 Financing [Member]

Stockholders Equity Note [Line Items]

Net proceeds from sale of common stock and warrants after transaction costs

$ 3,100

September 2016 Financing [Member]

Stockholders Equity Note [Line Items]

Aggregate gross proceeds from sale of common stock and warrants

$ 3,700

Net proceeds from sale of common stock and warrants after transaction costs

$ 3,200

Common Stock

Stockholders Equity Note [Line Items]

Issuance of common stock (in shares)

8,428

Common Stock | September 2018 Financing [Member]

Stockholders Equity Note [Line Items]

Issuance of common stock (in shares)

153,333

Shares issued, price per share (in usd per share)

$ 8.10

Transaction costs

$ 200

Common Stock | April 2018 Financing [Member]

Stockholders Equity Note [Line Items]

Transaction costs

$ 700

Common Stock | September 2017 Financing [Member]

Stockholders Equity Note [Line Items]

Issuance of common stock (in shares)

2,136,614

Shares issued, price per share (in usd per share)

$ 1.73

Aggregate gross proceeds from sale of common stock and warrants

$ 2,800

Transaction costs

$ 600

Common Stock | April 2017 Financing [Member]

Stockholders Equity Note [Line Items]

Number of securities called by each warrant (in shares)

0.75

Transaction costs

$ 1,100

Common Stock | September 2016 Financing [Member]

Stockholders Equity Note [Line Items]

Issuance of common stock (in shares)

1,082,402

Shares issued, price per share (in usd per share)

$ 3.45

$ 3.45

Transaction costs

$ 400

September 2018 Warrants [Member] | September 2018 Financing [Member]

Stockholders Equity Note [Line Items]

Warrant expiration period

5 years

September 2018 Placement Agent Warrants [Member] | September 2018 Financing [Member]

Stockholders Equity Note [Line Items]

Exercise price (in usd per share)

$ 0.3375

Warrant expiration period

5 years

April 2018 Warrants [Member] | April 2018 Financing [Member]

Stockholders Equity Note [Line Items]

Number of securities called by each warrant (in shares)

0.5

Exercise price (in usd per share)

$ 0.50

Warrant expiration period

5 years

April 2018 Placement Agent Warrants [Member] | April 2018 Financing [Member]

Stockholders Equity Note [Line Items]

Exercise price (in usd per share)

$ 0.625

Warrant expiration period

5 years

Warrants Expiring March 2020, Tranche 2

Stockholders Equity Note [Line Items]

Exercise price (in usd per share)

$ 18

Shares issuable upon exercise of warrants (in shares)

13,000

Warrants Expiring March 2020, Tranche 2 | September 2017 Financing [Member]

Stockholders Equity Note [Line Items]

Exercise price (in usd per share)

$ 2.16

$ 0.60

Warrant expiration period

2 years 6 months

Warrants Expiring March 2020, Tranche 1 [Member] | September 2017 Financing [Member]

Stockholders Equity Note [Line Items]

Exercise price (in usd per share)

$ 1.67

$ 0.60

Shares issuable upon exercise of warrants (in shares)

1,068,307

Warrant expiration period

2 years 6 months

Underwriter Warrants 2017 [Member] | April 2017 Financing [Member]

Stockholders Equity Note [Line Items]

Exercise price (in usd per share)

$ 1.75

Warrant expiration period

5 years

April 2017 Warrants [Member] | April 2017 Financing [Member]

Stockholders Equity Note [Line Items]

Exercise price (in usd per share)

$ 1.55

Warrant expiration period

5 years

Private Placement Warrants [Member] | September 2016 Financing [Member]

Stockholders Equity Note [Line Items]

Warrants, period in which warrants exercisable

6 months

Warrant expiration period

5 years 6 months

Placement Agent Warrants [Member] | September 2016 Financing [Member]

Stockholders Equity Note [Line Items]

Exercise price (in usd per share)

$ 4.3125

$ 4.3125

Warrant expiration period

5 years

Proceeds from issuance private placement warrants

$ 1,600

Payment of transaction costs

500

Non-cash transaction costs

100

Other financing costs

$ 300

February 2015 And January 2016 Warrants [Member]

Stockholders Equity Note [Line Items]

Fair value of warrants recorded as equity

$ 500

Change in fair value of warrant liability

$ 100

Common Stock

Stockholders Equity Note [Line Items]

Other financing costs

$ 200

Private Placement And Placement Agent Warrants [Member] | April 2017 Warrant Amendment [Member]

Stockholders Equity Note [Line Items]

Exercise price (in usd per share)

$ 1.55

Change in fair value of warrant liability

$ 200

Warrants Expiring January 2023, Tranche 2

Stockholders Equity Note [Line Items]

Exercise price (in usd per share)

$ 21.30

Shares issuable upon exercise of warrants (in shares)

3,000

Warrants Expiring March 2023

Stockholders Equity Note [Line Items]

Exercise price (in usd per share)

$ 12.60

Shares issuable upon exercise of warrants (in shares)

11,000

Warrants Expiring May 2023

Stockholders Equity Note [Line Items]

Exercise price (in usd per share)

$ 15

Shares issuable upon exercise of warrants (in shares)

80,000

Warrants Expiring May 2022

Stockholders Equity Note [Line Items]

Exercise price (in usd per share)

$ 46.50

Shares issuable upon exercise of warrants (in shares)

82,000

Warrants Expiring March 2023, Tranche 2

Stockholders Equity Note [Line Items]

Exercise price (in usd per share)

$ 21.30

Shares issuable upon exercise of warrants (in shares)

4,000

Warrants Expiring January 2023

Stockholders Equity Note [Line Items]

Exercise price (in usd per share)

$ 12.60

Shares issuable upon exercise of warrants (in shares)

11,000

Warrants Expiring July 2025

Stockholders Equity Note [Line Items]

Exercise price (in usd per share)

$ 492

Shares issuable upon exercise of warrants (in shares)

1,000

Warrants Expiring March 2024 Tranche 3

Stockholders Equity Note [Line Items]

Exercise price (in usd per share)

$ 12

Shares issuable upon exercise of warrants (in shares)

89,000

Warrants Expiring March 2023, Tranche 3

Stockholders Equity Note [Line Items]

Exercise price (in usd per share)

$ 18.90

Shares issuable upon exercise of warrants (in shares)

12,000

Warrants Expiring March 2024 Tranche 2

Stockholders Equity Note [Line Items]

Exercise price (in usd per share)

$ 9

Shares issuable upon exercise of warrants (in shares)

115,000

Warrants Expiring April 2022

Stockholders Equity Note [Line Items]

Exercise price (in usd per share)

$ 52.50

Shares issuable upon exercise of warrants (in shares)

8,000

Warrants Expiring October 2024

Stockholders Equity Note [Line Items]

Exercise price (in usd per share)

$ 387

Shares issuable upon exercise of warrants (in shares)

1,000

Warrants Expiring March 2024

Stockholders Equity Note [Line Items]

Exercise price (in usd per share)

$ 10.14

Shares issuable upon exercise of warrants (in shares)

8,000

Warrants Cancelled [Member]

Stockholders Equity Note [Line Items]

Fair value of warrants recorded as equity

$ 600

September 2018 Warrants And Placement Agent Warrants [Member]

Stockholders Equity Note [Line Items]

Fair value of warrants recorded as equity

$ 900

September 2018 Warrants, Tranche 1 [Member] | September 2018 Financing [Member]

Stockholders Equity Note [Line Items]

Exercise price (in usd per share)

$ 0.30

Shares issuable upon exercise of warrants (in shares)

3,450,000

September 2018 Warrants, Tranche 2 [Member] | September 2018 Financing [Member]

Stockholders Equity Note [Line Items]

Exercise price (in usd per share)

$ 0.40

Shares issuable upon exercise of warrants (in shares)

2,677,160

April 2018 Warrants And Placement Agent Warrants [Member]

Stockholders Equity Note [Line Items]

Fair value of warrants recorded as equity

$ 1,200

Stockholders' Equity - July 201

Stockholders' Equity - July 2016 Aspire Common Stock Purchase Agreement (Details)	Jul. 05, 2016USD ($)shares	Jul. 31, 2016USD ($)closing_priceday$ / sharesshares	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Sep. 30, 2018USD ($)shares
Stockholders Equity Note [Line Items]
Transaction costs			$ 690,000	$ 1,392,000
Aspire Capital Fund, LLC [Member]
Stockholders Equity Note [Line Items]
Common stock purchase agreement, shares authorized, amount		$ 7,000,000
Common stock purchase agreement, term		24 months
Shares issued (in shares) | shares	5,063
Shares issued, value	$ 600,000
Issuance of common stock (in shares) | shares	253,165				500,000
Issuance of common stock, value	$ 1,000,000				$ 1,200,000
Transaction costs		$ 100,000
Common stock purchase agreement, number of closing prices averaged to determine sale price (in closing prices) | closing_price		3
Common stock purchase agreement, number of days prior to stock purchase date for stock price assessment (in days) | day		12
Sale price measurement period		12 days
Share price, floor price required to use committed equity financing (in usd per share) | $ / shares		$ 1
Common stock purchase agreement, VWAP purchase, share price threshold (higher than) (in usd per share) | $ / shares		$ 3
Common stock purchase agreement, VWAP purchase, percentage of shares traded		30.00%
Common stock purchase agreement, VWAP purchase, percentage of weighted average price		97.00%
Common stock purchase agreement, maximum amount of shares to be sold (in shares) | shares		1,200,000
Common stock purchase agreement, maximum amount of shares to be sold, percentage of outstanding shares		19.99%
Aspire Capital Fund, LLC [Member] | Common Stock
Stockholders Equity Note [Line Items]
Stocked issued during period, weighted average cost per share (in usd per share) | $ / shares		$ 3.82

Stockholders' Equity - January

Stockholders' Equity - January 2016 Financing (Details) $ / shares in Units, $ in Millions	1 Months Ended		3 Months Ended	12 Months Ended
	Mar. 31, 2016USD ($)	Jan. 31, 2016USD ($)shares	Sep. 30, 2016USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2018$ / shares
Stockholders Equity Note [Line Items]
Aggregate offering price | $		$ 10
Aggregate gross proceeds from sale of common stock and warrants | $	$ 7.8	$ 2.2
Payments of transaction costs | $			$ 0.4
Common Stock
Stockholders Equity Note [Line Items]
Common stock, maximum number of shares to be purchased (in shares) | shares		1,136,364
Issuance of common stock (in shares) | shares		8,428
Warrant | Fair Value, Inputs, Level 3 [Member]
Stockholders Equity Note [Line Items]
Fair value of warrants issued during the period | $		$ 4.8
Common Stock
Stockholders Equity Note [Line Items]
Maximum number of warrants to be purchased (in shares) | shares		18,939
Warrants issued (in shares) | shares		126,421
Payments of transaction costs | $	$ 0.2
Common Stock | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Risk Free Interest Rate [Member]
Stockholders Equity Note [Line Items]
Warrants, measurement input	0.014	0.016
Common Stock | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Option Volatility [Member]
Stockholders Equity Note [Line Items]
Warrants, measurement input	0.994	1.019
Common Stock | Valuation Technique, Option Pricing Model [Member] | Measurement Input, Expected Dividend Rate [Member]
Stockholders Equity Note [Line Items]
Warrants, measurement input	0	0
Common Stock | Warrant | Fair Value, Inputs, Level 3 [Member]
Stockholders Equity Note [Line Items]
Fair value adjustment for modification | $				$ 0.7
Warrants Expiring May 2022
Stockholders Equity Note [Line Items]
Exercise price (in usd per share)					$ 46.50
Warrants Expiring March 2023, Tranche 2
Stockholders Equity Note [Line Items]
Exercise price (in usd per share)					21.30
Warrants Expiring January 2023
Stockholders Equity Note [Line Items]
Exercise price (in usd per share)					12.60
Warrants Expiring March 2023, Tranche 3
Stockholders Equity Note [Line Items]
Exercise price (in usd per share)					18.90
Warrants Expiring March 2020, Tranche 2
Stockholders Equity Note [Line Items]
Exercise price (in usd per share)					18
Warrants Expiring March 2024
Stockholders Equity Note [Line Items]
Exercise price (in usd per share)					10.14
Warrants Expiring January 2023, Tranche 2
Stockholders Equity Note [Line Items]
Exercise price (in usd per share)					21.30
Warrants Expiring March 2023
Stockholders Equity Note [Line Items]
Exercise price (in usd per share)					12.60
Warrants Expiring May 2023
Stockholders Equity Note [Line Items]
Exercise price (in usd per share)					15
Warrants Expiring July 2025
Stockholders Equity Note [Line Items]
Exercise price (in usd per share)					492
Warrants Expiring March 2024 Tranche 3
Stockholders Equity Note [Line Items]
Exercise price (in usd per share)					12
Warrants Expiring April 2022
Stockholders Equity Note [Line Items]
Exercise price (in usd per share)					52.50
Warrants Expiring October 2024
Stockholders Equity Note [Line Items]
Exercise price (in usd per share)					387
Warrants Expiring March 2024 Tranche 2
Stockholders Equity Note [Line Items]
Exercise price (in usd per share)					$ 9

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Warrant Activity (Details) shares in Thousands	12 Months Ended
	Dec. 31, 2018$ / sharesshares
Common Shares Issuable upon Exercise
Outstanding, beginning balance (in shares) | shares	236
Issued (in shares) | shares	342
Exercised (in shares) | shares	(35)
Cancelled (in shares) | shares	(107)
Outstanding, ending balance (in shares) | shares	437
Exercisable at balance sheet date (in shares) | shares	225
Weighted Average Exercise Price
Outstanding, beginning balance (in usd per share) | $ / shares	$ 117.30
Issued (in usd per share) | $ / shares	12.30
Exercised (in usd per share) | $ / shares	44.40
Cancelled (in usd per share) | $ / shares	119.70
Outstanding, ending balance (in usd per share) | $ / shares	20.70
Exercisable at balance sheet date (in dollars per share) | $ / shares	$ 30.30

Stockholders' Equity - Warrants

Stockholders' Equity - Warrants Outstanding by Expiration Date (Details) shares in Thousands	Dec. 31, 2018$ / sharesshares
Class of Warrant or Right [Line Items]
Shares issuable upon exercise (in shares)	437
Warrants Expiring March 2020, Tranche 2
Class of Warrant or Right [Line Items]
Shares issuable upon exercise (in shares)	13
Exercise price (in USD per share) | $ / shares	$ 18
Warrants Expiring April 2022
Class of Warrant or Right [Line Items]
Shares issuable upon exercise (in shares)	8
Exercise price (in USD per share) | $ / shares	$ 52.50
Warrants Expiring May 2022
Class of Warrant or Right [Line Items]
Shares issuable upon exercise (in shares)	82
Exercise price (in USD per share) | $ / shares	$ 46.50
Warrants Expiring January 2023
Class of Warrant or Right [Line Items]
Shares issuable upon exercise (in shares)	11
Exercise price (in USD per share) | $ / shares	$ 12.60
Warrants Expiring January 2023, Tranche 2
Class of Warrant or Right [Line Items]
Shares issuable upon exercise (in shares)	3
Exercise price (in USD per share) | $ / shares	$ 21.30
Warrants Expiring March 2023
Class of Warrant or Right [Line Items]
Shares issuable upon exercise (in shares)	11
Exercise price (in USD per share) | $ / shares	$ 12.60
Warrants Expiring March 2023, Tranche 2
Class of Warrant or Right [Line Items]
Shares issuable upon exercise (in shares)	4
Exercise price (in USD per share) | $ / shares	$ 21.30
Warrants Expiring March 2023, Tranche 3
Class of Warrant or Right [Line Items]
Shares issuable upon exercise (in shares)	12
Exercise price (in USD per share) | $ / shares	$ 18.90
Warrants Expiring May 2023
Class of Warrant or Right [Line Items]
Shares issuable upon exercise (in shares)	80
Exercise price (in USD per share) | $ / shares	$ 15
Warrants Expiring March 2024
Class of Warrant or Right [Line Items]
Shares issuable upon exercise (in shares)	8
Exercise price (in USD per share) | $ / shares	$ 10.14
Warrants Expiring March 2024 Tranche 2
Class of Warrant or Right [Line Items]
Shares issuable upon exercise (in shares)	115
Exercise price (in USD per share) | $ / shares	$ 9
Warrants Expiring March 2024 Tranche 3
Class of Warrant or Right [Line Items]
Shares issuable upon exercise (in shares)	89
Exercise price (in USD per share) | $ / shares	$ 12
Warrants Expiring October 2024
Class of Warrant or Right [Line Items]
Shares issuable upon exercise (in shares)	1
Exercise price (in USD per share) | $ / shares	$ 387
Warrants Expiring July 2025
Class of Warrant or Right [Line Items]
Shares issuable upon exercise (in shares)	1
Exercise price (in USD per share) | $ / shares	$ 492

Equity Compensation Plans - Nar

Equity Compensation Plans - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options exercisable (shares)	15,076	9,777
Stock options exercised (shares)	0	0
Fair vale of options vested in period	$ 0.1	$ 0.8
Stock options granted (shares)	23,000
Dividend yield	0.00%	0.00%
Two Thousand Twelve Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common shares authorized for issuance (shares)	67,731
Common shares available for future grants (shares)	10,872
Two Thousand Twelve Incentive Plan [Member] | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options vesting period	1 year
Two Thousand Twelve Incentive Plan [Member] | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options vesting period	4 years
Term of options	10 years
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to equity awards	$ 0.6
Period of recognition for unrecognized compensation costs (in years)	2 years 252 days
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of awards vested in period	$ 0.3	$ 0.4
Unrecognized compensation cost related to equity awards	$ 0.6
Period of recognition for unrecognized compensation costs (in years)	29 days

Equity Compensation Plans - Sum

Equity Compensation Plans - Summary of Stock Option Activity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Number of Shares
Outstanding, beginning of period (shares)	12,000
Granted in Period (shares)	23,000
Exercised in Period (shares)	0	0
Cancelled (shares)	(6,000)
Outstanding, end of period (shares)	29,000	12,000
Vested and expected to vest, end of period (shares)	29,000
Exercisable, end of period (shares)	15,076	9,777
Weighted Average Exercise Price
Outstanding, beginning of period (USD per share)	$ 521.10
Granted in Period (USD per share)	63.30
Exercised in Period (USD per share)	0
Cancelled (USD per share)	183.90
Outstanding, end of period (USD per share)	230.10	$ 521.10
Vested and expected to vest stock, end of period (USD per share)	230.10
Exercisable, end of period (USD per share)	$ 375
Weighted Average Remaining Contractual Life (in years)
Outstanding (in years)	7 years 288 days	6 years 252 days
Weighted Average Remaining Contractual Life (in years) of vested and expected to vest stock options	7 years 288 days
Weighted Average Remaining Contractual Life (in years) of exercisable stock options	6 years 288 days
Total Aggregate Intrinsic Value
Total aggregate intrinsic value shares outstanding	$ 0
Total aggregate intrinsic value of vested or expected to vest stock options	0
Total aggregate intrinsic value of exercisable stock options	$ 0

Equity Compensation Plans - S_2

Equity Compensation Plans - Summary of Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs) [Member]	12 Months Ended
	Dec. 31, 2018$ / sharesshares
Number of Shares
Nonvested, beginning of period (shares) | shares	24,000
Granted (shares) | shares	0
Vested (shares) | shares	(14,000)
Forfeited (shares) | shares	(1,000)
Nonvested, end of period (shares) | shares	9,000
Weighted Average Grant Date Fair Value
Nonvested, beginning of period (USD per share) | $ / shares	$ 47.10
Granted (USD per share) | $ / shares	0
Vested (USD per share) | $ / shares	49.50
Forfeited (USD per share) | $ / shares	39.60
Nonvested, end of period (USD per share) | $ / shares	$ 43.80

Equity Compensation Plans - Ass

Equity Compensation Plans - Assumptions Of Black-Scholes Option Grant (Details) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Share Based Payment Award Stock Options Valuation Assumptions [Line Items]
Risk-free interest rate	2.30%
Volatility, minimum	98.00%
Volatility, maximum	105.00%
Dividend yield	0.00%	0.00%
Forfeiture rate	11.33%
Weighted average fair value	$ 49.88
Minimum
Share Based Payment Award Stock Options Valuation Assumptions [Line Items]
Expected term (in years)	5 years 3 months
Maximum
Share Based Payment Award Stock Options Valuation Assumptions [Line Items]
Expected term (in years)	6 years 29 days

Equity Compensation Plans - Sto

Equity Compensation Plans - Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 1,301	$ 1,138
Research and Development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	336	227
General and Administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 965	$ 911

Related Party Transactions - Na

Related Party Transactions - Narrative (Details) $ in Millions	12 Months Ended
	Dec. 31, 2018USD ($)
Related Party Transactions [Abstract]
Sublease, term of contract (years)	1 year
Future sublease payments receivable from related party	$ 0.4
Related Party Transaction, Description of Transaction	</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">IRRAS AB ("IRRAS") is a commercial stage medical technology company of which a current director of the Company, Kleanthis G. Xanthopoulos, Ph.D., is currently the President, Chief Executive Officer and director. In January 2018, the Company and IRRAS entered into a Sublease, pursuant to which the Company subleased to IRRAS excess capacity in its corporate headquarters. The sublease has a term of two years and aggregate payments due to the Company of approximately $0.3 million. On October 30, 2018, the Company and IRRAS entered into an amended and restated sublease, commencing January 1, 2019, pursuant to which the Company agreed to sublease to IRRAS the remainder of its current corporate headquarters (the "IRRAS Restated Sublease"), which satisfied a closing condition related to the merger. The IRRAS Restated Sublease has a term of one year and provides for aggregate payments due to the Company of approximately $0.4 million, which approximate fair value.</p> <p style="margin: 0"> </p> <p style="margin: 0"></p> <p style="margin: 0"> </p>" id="sjs-B6">&lt;p style="margin: 0">&lt;/p> &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">IRRAS AB (&#34;IRRAS&#34;) is a commercial stage medical technology company of which a current director of the Company, Kleanthis G. Xanthopoulos, Ph.D., is currently the President, Chief Executive Officer and director. In January 2018, the Company and IRRAS entered into a Sublease, pursuant to which the Company subleased to IRRAS excess capacity in its corporate headquarters. The sublease has a term of two years and aggregate payments due to the Company of approximately $0.3 million. On October 30, 2018, the Company and IRRAS entered into an amended and restated sublease, commencing January 1, 2019, pursuant to which the Company agreed to sublease to IRRAS the remainder of its current corporate headquarters (the &#34;IRRAS Restated Sublease&#34;), which satisfied a closing condition related to the merger. The IRRAS Restated Sublease has a term of one year and provides for aggregate payments due to the Company of approximately $0.4 million, which approximate fair value.&lt;/p> &lt;p style="margin: 0">&#160;&lt;/p> &lt;p style="margin: 0">&lt;/p> &lt;p style="margin: 0">&#160;&lt;/p>

Income Taxes - Deferred Tax Ass

Income Taxes - Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Net operating tax loss and capital loss carryforwards	$ 25,549	$ 23,463
Capitalized research and development costs	4,194	4,620
Research and development tax credits	1,937	1,923
Other accruals and reserves	494	721
Basis of intangible assets	3,136	3,658
Total deferred tax asset	35,310	34,385
Less valuation allowance	(35,310)	(34,385)
Net deferred tax asset	$ 0	$ 0

Income Taxes - Recognition Of U

Income Taxes - Recognition Of Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Unrecognized Tax Benefits [Roll Forward]
Beginning balance	$ 713	$ 3,047
Change in current period positions	13	34
Change in prior period positions	(8)	(2,368)
Ending balance	$ 718	$ 713

Income Taxes - Reconciliation O

Income Taxes - Reconciliation Of Income Taxes (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Federal statutory tax rate	(21.00%)	(34.00%)
Change in rate	0.00%	165.00%
Valuation allowance	10.00%	(360.00%)
Deferred tax true-ups	5.00%	227.00%
Revaluation of warrants	0.00%	2.00%
Permanent differences	7.00%	1.00%
Tax credits	(1.00%)	(1.00%)
Income tax expense	(0.00%)	(0.00%)

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Operating Loss Carryforwards [Line Items]
Federal operating loss carryforwards and tax credit carryforwards deferred tax asset	$ 27.5	$ 25.4
Tax Credit Carryforward, Description	The Company has incurred losses since inception, which have generated net operating loss carryforwards and capital loss carryforwards of approximately $118.4 million and $9.8 million for federal and California income tax purposes, respectively. These carryforwards are available to offset future taxable income and expire beginning in 2019 through 2037 for federal income tax purposes and beginning in 2030 through 2033 for California income tax purposes. Also, Federal net operating loss carryforwards that were generated in 2018 have an indefinite carryforward period. In addition, the Company has research and development tax credit carryforwards for federal and state income tax purposes as of December 31, 2018 of $1.8 million and $1.0 million, respectively. The federal credits will begin to expire in 2019 unless utilized and the state credits have an indefinite life.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"> </p>" id="sjs-B5">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company has incurred losses since inception, which have generated net operating loss carryforwards and capital loss carryforwards of approximately $118.4 million and $9.8 million for federal and California income tax purposes, respectively.&#160;These carryforwards are available to offset future taxable income and expire beginning in 2019 through 2037 for federal income tax purposes and beginning in 2030 through 2033 for California income tax purposes. Also, Federal net operating loss carryforwards that were generated in 2018 have an indefinite carryforward period. In addition, the Company has research and development tax credit carryforwards for federal and state income tax purposes as of December 31, 2018 of $1.8 million and $1.0 million, respectively. The federal credits will begin to expire in 2019 unless utilized and the state credits have an indefinite life.&lt;/p> &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;&lt;/p> &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&lt;/p> &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;&lt;/p>
Tax Credit Carryforward, Limitations on Use	Utilization of the loss carryforwards may be subject to a substantial annual limitation due to ownership change limitations that may have occurred or that could occur in the future, as required under Internal Revenue Code Section 382 ("Section 382"), as well as similar state and foreign provisions. These ownership changes may limit the amount of loss carryforwards that can be utilized annually to offset future taxable income. In general, an "ownership change" as defined by Section 382 results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders or public groups. Since the Company's formation, the Company has raised capital through the issuance of capital stock on several occasions which, combined with the purchasing stockholders' subsequent disposition of those shares, likely resulted in such an ownership change, or could result in an ownership change in the future upon subsequent disposition.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">During the first quarter of 2017, the Company completed a study to assess whether an ownership change occurred and determined that there have been multiple ownership changes since the Company's formation. As a result, utilization of the loss carryforwards are subject to an annual limitation under Section 382, which was determined by first multiplying the value of the Company's stock at the time of the ownership change by the applicable long-term, tax-exempt rate. These limitations resulted in the expiration of the majority of the Company's loss carryforwards. These loss carryforwards that have expired due to these limitations have been removed from deferred tax assets with a corresponding reduction of the valuation allowance with no net effect on income tax expense or the effective tax rate. Despite the assessment completed during the first quarter of 2017, additional ownership changes may have occurred subsequent to the completion of the study, which would continue to limit utilization of any future loss carryforwards.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"> </p>" id="sjs-B6">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">Utilization of the loss carryforwards may be subject to a substantial annual limitation due to ownership change limitations that may have occurred or that could occur in the future, as required under Internal Revenue Code Section 382 (&#34;Section&#160;382&#34;), as well as similar state and foreign provisions. These ownership changes may limit the amount of loss carryforwards that can be utilized annually to offset future taxable income. In general, an &#34;ownership change&#34; as defined by Section&#160;382 results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders or public groups. Since the Company's formation, the Company has raised capital through the issuance of capital stock on several occasions which, combined with the purchasing stockholders' subsequent disposition of those shares, likely resulted in such an ownership change, or could result in an ownership change in the future upon subsequent disposition.&lt;/p> &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">During the first quarter of 2017, the Company completed a study to assess whether an ownership change occurred and determined that there have been multiple ownership changes since the Company's formation. As a result, utilization of the loss carryforwards are subject to an annual limitation under Section&#160;382, which was determined by first multiplying the value of the Company's stock at the time of the ownership change by the applicable long-term, tax-exempt rate. These limitations resulted in the expiration of the majority of the Company's loss carryforwards. These loss carryforwards that have expired due to these limitations have been removed from deferred tax assets with a corresponding reduction of the valuation allowance with no net effect on income tax expense or the effective tax rate. Despite the assessment completed during the first quarter of 2017, additional ownership changes may have occurred subsequent to the completion of the study, which would continue to limit utilization of any future loss carryforwards.&lt;/p> &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;&lt;/p> &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;&lt;/p>
Domestic Tax Authority
Operating Loss Carryforwards [Line Items]
Operating loss and capital loss carryforwards	$ 118.4
Domestic Tax Authority | Research Tax Credit Carryforward
Operating Loss Carryforwards [Line Items]
Tax credit carryforward	1.8
State and Local Jurisdiction
Operating Loss Carryforwards [Line Items]
Operating loss and capital loss carryforwards	9.8
State and Local Jurisdiction | Research Tax Credit Carryforward
Operating Loss Carryforwards [Line Items]
Tax credit carryforward	$ 1

Commitments and Contingencies -

Commitments and Contingencies - Narrative (Details) - USD ($) $ in Thousands	Jul. 25, 2017	Jul. 25, 2017	Dec. 31, 2015	Dec. 31, 2011	Dec. 31, 2018	Dec. 31, 2017
Commitments And Contingencies [Line Items]
Future sublease payments receivable from related party					$ 400
Sublease, term of contract					2 years
Rent expense					$ 3	$ 3
San Diego Headquarters
Commitments And Contingencies [Line Items]
Operating lease, agreement period (in years)				5 years
Operating lease, renewal option (in years)				3 years
Operating lease, monthly rent				$ 24
Operating lease, rent expense percentage of annual escalation				3.00%
Operating lease, rent abatement period			6 months
Operating lease, rent abatement recovery period			60 months
Pending Litigation | Majorelle Case | Minimum
Commitments And Contingencies [Line Items]
Loss contingency, damages sought	$ 1,000	$ 1

Commitments and Contingencies_2

Commitments and Contingencies - Future Minimum Rental Payments Under Operating Leases (Details) $ in Thousands	Dec. 31, 2018USD ($)
Future Minimum Rental Payments
2019	$ 374
2020	32
Total	$ 406

Litigation - Narrative (Details

Litigation - Narrative (Details) - USD ($) $ in Thousands	Jul. 25, 2017	Jul. 25, 2017
Pending Litigation [Member] | Majorelle Case [Member] | Minimum
Loss Contingencies [Line Items]
Loss contingency, damages sought	$ 1,000	$ 1

Subsequent Events (Narrative) (

Subsequent Events (Narrative) (Details)	1 Months Ended
	Jan. 31, 2019
Subsequent Events Narrative
Subsequent Event, Date	Jan. 24, 2019
Subsequent Event, Description	<b>Merger</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On January 24, 2019, the Company completed the Merger with STI, pursuant to which Merger Sub merged with and into STI, with STI surviving as the Company's wholly-owned subsidiary. See note 2 to the consolidated financial statements above for additional information on the Merger.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><b>Severance</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company paid approximately $1.8 million in January 2019 pursuant to certain employment agreements that triggered upon the completion of the Merger with STI.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"></p>" id="sjs-B5">&lt;p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0; text-align: justify">&lt;b>Merger&lt;/b>&lt;/p> &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&lt;/p> &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">On January 24, 2019, the Company completed the Merger with STI, pursuant to which Merger Sub merged with and into STI, with STI surviving as the Company's wholly-owned subsidiary. See note 2 to the consolidated financial statements above for additional information on the Merger.&lt;/p> &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&lt;b>Severance&lt;/b>&lt;/p> &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">The Company paid approximately $1.8 million in January 2019 pursuant to certain employment agreements that triggered upon the completion of the Merger with STI.&lt;/p> &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;&lt;/p> &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;&lt;/p> &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;&lt;/p> &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&lt;/p> &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;&lt;/p> &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;&lt;/p> &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;&lt;/p> &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&#160;&lt;/p> &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&lt;/p>